international journal of pharmaceutics

cumulative author and subject indexes
volumes 31–40

INTERNATIONAL JOURNAL OF PHARMACEUTICS

AIMS AND SCOPE

The INTERNATIONAL JOURNAL OF PHARMACEUTICS provides a medium for the publication of research results dealing with all aspects of Pharmaceutics including physical, chemical, analytical, biological and engineering studies related to drug delivery in its broadest sense. Such areas include:

1. Drug delivery systems
2. Physical pharmacy
3. Biopharmaceutics
4. Pharmacodynamics and pharmacokinetics as related to dosage form and drug delivery
5. Membrane function and transport
6. Biotechnology of drugs and dosage forms
7. Drug and prodrug design
8. Radiopharmaceuticals
9. Sterility and sterilization
10. Quality control of pharmaceuticals
11. Pharmaceutical analysis
12. Drug stability
13. Pharmaceutical technology
14. Descriptions/reviews of computer programs relating to the above areas

EDITORIAL POLICY

The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content.
Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

EDITORS IN CHIEF

For: Europe, Africa, Near East

P.F. D'ARCY
Department of Pharmacy,
Medical Biology Centre,
The Queen's University
of Belfast,
97 Lisburn Road,
Belfast BT9 7BL,
Northern Ireland,
U.K.

For: The Americas, Japan and Australia

W.I. HIGUCHI
Department of Pharmaceutics,
College of Pharmacy,
University of Utah,
Salt Lake City,
UT 84112,
U.S.A.

J.H. RYTTING
(Associate Editor)
Pharmaceutical Chemistry
Dept.,
School of Pharmacy,
University of Kansas,
Lawrence, KS 66045,
U.S.A.

EDITORIAL BOARD

G. Amidon (Ann Arbor, MI)
B.D. Anderson (Salt Lake City, UT)
G.S. Banker (Minneapolis, MN)
H. Boxenbaum (Cincinnati, OH)
H. Bundgaard (Copenhagen)
J.T. Carstensen (Madison, WI)
S.S. Davis (Nottingham)
A.T. Florence (Glasgow)
J.L. Fox (Salt Lake City, UT)
H.L. Fung (Amherst, NY)
D. Ganderton (London)
J. Hadgraft (Cardiff)
M. Hanano (Tokyo)
E.N. Hiestand (Kalamazoo, MI)
N.F.H. Ho (Kalamazoo, MI)
T.M. Jones (Dartford)
K. Knutson (Salt Lake City, UT)
G. Levy (Amherst, NY)
A. Li Wan Po (Belfast)
J.A. Mollica (Wilmington, DE)
T. Nagai (Tokyo)
I.H. Pitman (Parkville)
G. Poste (Philadelphia, PA)
B.J. Poulsen (Palo Alto, CA)
A.J. Repta (Lawrence, KS)
J.R. Robinson (Madison, WI)
T.J. Roseman (Morton Grove, IL)
R.C. Rowe (Macclesfield)
H. Sezaki (Kyoto)
J.E. Shaw (Palo Alto, CA)
E. Shefter (Wilmington, DE)
D.D. Shen (Seattle, WA)
E. Shotton (Berkhampstead)
J. Sjögren (Mölnlycke)
R.S. Summers (Pretoria)
D.J. Temple (Cardiff)
B. Testa (Lausanne)
K. Thoma (Munich)
R.F. Timoney (Dublin)
E. Tomlinson (Horsham)
G. Zografi (Madison, WI)

INSTRUCTIONS TO AUTHORS

Submission of a paper to the International Journal of Pharmaceutics implies: (1) that it is not being submitted for publication elsewhere; (2) the transfer of the Copyright from the Author to the Publisher. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

Papers and original figures should be submitted plus **three copies** and accompanied by a letter of transmittal to one of the Editors in Chief.

TYPES OF PAPERS

(1) Full length papers.
(2) Short communications not exceeding 1500 words or equivalent space including figures and tables.
(3) Descriptions/reviews of computer programs useful to pharmaceutical scientists.
(4) Suggestions for Review Articles will be considered by the Editors-in-Chief.

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CUMULATIVE AUTHOR AND SUBJECT INDEXES
VOLUMES 31–40

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Editors in Chief

P.F. D'ARCY (Belfast, N. Ireland, U.K.) and W.I. HIGUCHI (Salt Lake City, UT, U.S.A.)
(Associate Editor: J.H. RYTTING, Lawrence, KS, U.S.A.)

Editorial Board

G. AMIDON (Ann Arbor, MI, U.S.A.)
B.D. ANDERSON (Salt Lake City, UT, U.S.A.)
G.S. BANKER (Minneapolis, MN, U.S.A.)
H. BOXENBAUM (Cincinnati, OH, U.S.A.)
H. BUNDGAARD (Copenhagen, Denmark)
J.T. CARSTENSEN (Madison, WI, U.S.A.)
S.S. DAVIS (Nottingham, U.K.)
A.T. FLORENCE (Glasgow, U.K.)
J.L. FOX (Salt Lake City, UT, U.S.A.)
H.L. FUNG (Amherst, NY, U.S.A.)
D. GANDERTON (London, U.K.)
J. HADGRAFT (Cardiff, U.K.)
M. HANANO (Tokyo, Japan)
E.N. HIESTAND (Kalamazoo, MI, U.S.A.)
N.F.H. HO (Kalamazoo, MI, U.S.A.)
T.M. JONES (Dartford, U.K.)
K. KNUTSON (Salt Lake City, UT, U.S.A.)
G. LEVY (Amherst, NY, U.S.A.)
A. LI WAN PO (Belfast, N. Ireland)
J.A. MOLLICA (Wilmington, DE, U.S.A.)
T. NAGAI (Tokyo, Japan)
I.H. PITMAN (Parkville, Australia)
G. POSTE (Philadelphia, PA, U.S.A.)
B.J. POULSEN (Palo Alto, CA, U.S.A.)
A.J. REPTA (Lawrence, KS, U.S.A.)
J.R. ROBINSON (Madison, WI, U.S.A.)
T.J. ROSEMAN (Morton Grove, IL, U.S.A.)
R.C. ROWE (Macclesfield, U.K.)
H. SEZAKI (Kyoto, Japan)
J.E. SHAW (Palo Alto, CA, U.S.A.)
E. SHEFTER (San Francisco, CA, U.S.A.)
D.D. SHEN (Seattle, WA, U.S.A.)
E. SHOTTON (Berkhampstead, U.K.)
J. SJÖGREN (Mölnlycke, Sweden)
R.S. SUMMERS (Pretoria, South Africa)
B. TESTA (Lausanne, Switzerland)
D.J. TEMPLE (Cardiff, U.K.)
K. THOMA (Munich, F.R.G.)
R.F. TIMONEY (Dublin, Ireland)
E. TOMLINSON (Horsham, U.K.)
G. ZOGRAFI (Madison, WI, U.S.A.)

AUTHOR AND SUBJECT INDEXES
VOLUMES 31–40

ELSEVIER SCIENCE PUBLISHERS B.V. – AMSTERDAM

© 1988, Elsevier Science Publishers B.V. (Biomedical Division)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the Publisher. This transfer will ensure the widest possible dissemination of information.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the Publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in Article 17, Paragraph 2 of the Dutch Copyright Act of 1912, and in the Royal Decree of June 20, 1974 (S. 351) pursuant to Article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US$ 2.25, also payable through the Center. This consent does not extend to other kinds of copying such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the Publisher for such copying.

Printed in the Netherlands

International Journal of Pharmaceutics, (1988) 1–18
Elsevier

Author Index

Abra, R.M., see Schreier, H. (37) 233
Ackermann, C. and Flynn, G.L.
Ether–water partitioning and permeability through nude mouse skin in vitro. I. Urea, thiourea, glycerol and glucose (36) 61
Ackermann, C., Flynn, G.L. and Smith, W.M.
Ether–water partitioning and permeability through nude mouse skin in vitro. II. Hydrocortisone 21-*n*-alkyl esters, alkanols and hydrophilic compounds (36) 67
Ackermann, C., see Du Plessis, J. (34) 173
Acree, W.E., Jr., Pontikos, N.M. and Judy, C.L.
Solubility in binary solvent systems. 6. Prediction of naphthalene and biphenyl solubilities based on the Wilson model (31) 225
Adelusi, S.A.
Evaluation of the extraction of chloroquine from biological samples by different organic solvents (35) 173
Ahlgren, R., see Nicklasson, M. (37) 195
Ahmed, I. and Patton, T.F.
Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption (38) 9
Ahmed, I. and Patton, T.F.
Selective intraocular delivery of liposome encapsulated inulin via the non-corneal absorption route (34) 163
Aiache, J.-M., Islasse, M., Beyssac, E., Aiache, S., Renoux, R. and Kantelip, J.-P.
Kinetics of indomethacin release from suppositories. In vitro–in vivo correlation (39) 235
Aiache, S., see Aiache, J.-M. (39) 235
Akbarieh, M. and Tawashi, R.
Morphic features of solid particles after micronization in the fluid energy mill (35) 81
Al-Adham, I.S.I. and Gilbert, P.
Effect of polyvinylpyrrolidone molecular weight upon the antimicrobial activity of povidone–iodine antiseptics (34) 45
Al-Angary, A.A., see Gouda, M.W. (37) 277
Al-Dujaili, H., Florence, A.T. and Salole, E.G.
In vitro assessment of the adhesiveness of film-coated tablets (34) 67
Al-Dujaili, H., Florence, A.T. and Salole, E.G.
The adhesiveness of proprietary tablets and capsules to porcine oesophageal tissue (34) 75
Al-Khamis, K., Davis, S.S. and Hadgraft, J.
In vitro–in vivo correlations for the percutaneous absorption of salicylates (40) 111
Al-Shora, H.I., see Moustafa, M.A. (34) 207
Al-Turk, W., see Shaheen, O. (38) 123
Albers, W.M., see Duchateau, G.S.M.J.E. (34) 131
Alderborn, G., Lång, P.O., Sågström, A. and Kristensen, A.
Compression characteristics of granulated materials. I. Fragmentation propensity and compactibility of some granulations of a high dosage drug (37) 155
Alexander, J., see Gogate, U.S. (40) 235
Allwood, M.C. and Plane, J.H.
The wavelength-dependent degradation of vitamin A exposed to ultraviolet radiation (31) 1
Allwood, M.C.
Sorption of parenteral nitrates during administration with a syringe pump and extension set (39) 183
Alonso, M.J., see Henry-Michelland, S. (35) 121
Amidon, G.E., see Dick, C.F. (38) 23
Anderson, L., see McCafferty, D.F. (38) 59
Ando, H., Ohwaki, T., Ishii, M., Watanabe, S. and Miyake, Y.
Crystallization of theophylline in tablets (34) 153
Andremont, A., see Henry-Michelland, S. (35) 121
Andrieu, V., see Damgé, C. (36) 121
Antonelli, I., see Rochat, M.H. (38) 79
Apostolelli, E., see Macheras, P. (36) 73
Aprahamian, M., see Damgé, C. (36) 121
Araki, Y., see Fukuda, T. (36) 1
Archer, W.I., see Kohli, R. (36) 91
Armand, J.Y., Magnard, F., Bouzon, J., Rollet, J., Taverdet, J.L. and Vergnaud, J.M.
Modelling of drug release in gastric liquid from spheric galenic forms with Eudragit matrix (40) 33
Armstrong, N.A., Gebre-Mariam, T. and James, K.C.
An apparatus for investigating drug migration into gelatin capsule shells (34) 125
Aronhime, M., see Benita, S. (33) 71
Artursson, P. and Sjöholm, I.
Effect of opsonins on the macrophage uptake of polyacrylstarch microparticles (32) 165
Artursson, P., see Edman, P. (34) 225
Artursson, P., see Stjärnkvist, P. (40) 215
Asuero, A.G., Marques, M.L. and Navas, M.J.
Spectrophotometric determination of cobalt in multivitaminic preparations with dipyridylglyoxal mono(2-pyridyl)hydrazone (40) 43
Asuero, A.G., Navas, M.J., Herrador, M.A. and Recamales, A.F.
Spectrophotometric evaluation of acidity constants of isonicotinic acid (34) 81
Atassi, G., see Dubois, J.G. (35) 219

0378-5173/88/$03.50 © 1988 Elsevier Science Publishers B.V. (Biomedical Division)

Atsumi, R., see Takakura, Y. (37) 145
Attia, M.A., see Kassem, M.A. (32) 47
Audus, K.L., see Rim, S. (32) 79
Aungst, B.J., Myers, M.J., Shefter, E. and Shami, E.G.
Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters (38) 199
Aungst, B.J., Rogers, N.J. and Shefter, E.
Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides (33) 225
Aungst, B.J., see Hussain, M.A. (36) 127
Awazu, S., see Kajii, H. (33) 253
Awidi, A., see Shaheen, O. (38) 123
Ayres, J.W., see Tavipatana, W. (38) 139

Babhair, S.A., see Gouda, M.W. (37) 277
Babhair, S.A., see Moustafa, M.A. (36) 187
Baichwal, A.R., see Staniforth, J.N. (40) 267
Balboni, G., see Damgé, C. (36) 121
Barry, B.W., see Michniak-Mikolajczak, B.B. (31) 247
Basseleur, S.W.J., see Duchateau, G.S.M.J.E. (39) 87
Baveja, S.K. and Rao, K.V.R.
Sustained release tablet formulation of centperazine (31) 169
Baveja, S.K., Rao, K.V.R. and Padmalatha Devi, K.
Zero-order release hydrophilic matrix tablets of β-adrenergic blockers (39) 39
Bechard, S. and McMullen, J.N.
Diffusional release of a solute from a porous polymeric matrix (32) 71
Bechard, S. and McMullen, J.N.
Pectin–gelatin microglobules: effect of a cross-linking agent (formaldehyde) on in vitro dissolution rate (31) 91
Becker, A.R., see Powell, M.F. (35) 61
Beezer, A.E., Gooch, C.A., Hunter, W.H., Lima, M.C.P. and Smith, B.V.
Quantitative structure–activity relationships: a group additivity scheme for biological response of *E. coli* to the action of *o*-, *m*- and *p*-alkoxyphenol (38) 251
Beihn, R., see Sangekar, S. (35) 187
Beihn, R.M., see Parr, A. (32) 251
Beijnen, J.H., Fokkens, R.H., Rosing, H. and Underberg, W.J.M.
Degradation of mitomycin C in acid phosphate and acetate buffer solutions (32) 111
Beijnen, J.H., Potman, R.P., Van Ooijen, R.D., Driebergen, R.J., Voskuilen, M.C.H., Renema, J. and Underberg, W.J.M.
Structure elucidation and characterization of daunorubicin degradation products (34) 247
Beijnen, J.H., Van der Houwen, O.A.G.J. and Underberg, W.J.M.
Aspects of the degradation kinetics of doxorubicin in aqueous solution (32) 123
Beijnen, J.H., Van der Houwen, O.A.G.J., Voskuilen, M.C.H. and Underberg, W.J.M.
Aspects of the degradation kinetics of daunorubicin in aqueous solution (31) 75
Bell, G.D., see White, D.A. (40) 151
Benita, S., Dor, P., Aronhime, M. and Marom, G.
Permeability and mechanical properties of a new polymer: cellulose hydrogen phthalate (33) 71
Benjamin, E.J., Firestone, B.A., Schneider, J.A. and Lin, L.H.
Stabilization of the dipropionate ester of DHPG, 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine against enzymatic hydrolysis using complexation (35) 73
Benoit, J.P., see Dubernet, C. (35) 145
Berger, S., see Waser, P.G. (39) 213
Bergers, J.J., see Steerenberg, P.A. (40) 51
Betageri, G.V. and Rogers, J.A.
Thermodynamics of partitioning of β-blockers in the *n*-octanolbuffer and liposome systems (36) 165
Beyssac, E., see Aiache, J.-M. (39) 235
Bialer, M., see Hussein, Z. (37) 97
Birmančević, M., see Sekulović, D. (32) 269
Bisgaard, H., see Illum, L. (39) 189
Bjankova, R., see Bogdanova, S. (38) 99
Björk, E., see Edman, P. (34) 225
Bocci, V., Corradeschi, F., Naldini, A. and Lencioni, E.
Enteric absorption of human interferons α and β in the rat (34) 111
Bocci, V., Muscettola, M. and Naldini, A.
The lymphatic route. IV. Pharmacokinetics of human recombinant interferon α_2 and natural interferon β administered intradermally in rabbits (32) 103
Bodor, N., McCornack, J. and Brewster, M.E.
Improved delivery through biological membranes. XXII. Synthesis and distribution of brain-selective estrogen delivery systems (35) 47
Bogdanova, S., Bjankova, R., Minkov, E. and Rainova, L.
Influence of polyvinylpyrrolidone on the in vitro diffusion characteristics of tetraminol (38) 99
Bolhuis, G.K., see Vromans, H. (35) 29
Bolhuis, G.K., see Vromans, H. (39) 201
Bolhuis, G.K., see Vromans, H. (39) 207
Bond, S.W., see Wilson, C.G. (38) 221
Bonfils, A., see Heyman, M. (37) 33
Borchardt, R.T., see Rim, S. (32) 79
Bosch, H., see Vromans, H. (35) 29
Bourel, D., see Rolland, A. (39) 173
Bourne, D.W.A., see Kwon, K. (37) 219
Boussard, P., Devleeschouwer, M.J., Otten, M. and Dony, J.
Influence of chloramphenicol on the sensitivity of *Pseudomonas aeruginosa* to chloroxylenol and crystal violet (32) 91
Boussard, P., see Devleeschouwer, M.J. (32) 55
Bouzon, J., see Armand, J.Y. (40) 33
Bouzon, J., see Farah, N. (36) 81
Boye, T., see Harmia, T. (33) 187
Brewster, M.E., see Bodor, N. (35) 47
Brodin, A., see Fyhr, P. (40) 157
Brodin, A., see Fyhr, P. (40) 193
Brookes, L.G., see Gilbert, J.C. (32) 223
Brophy, M.R. and Deasy, P.B.
Application of the Higuchi model for drug release from dispersed matrices to particles of general shape (37) 41
Brunmark, A., see Stjärnkvist, P. (40) 215

Buchmann, M., see Huu-Phuoc, N. (34) 217
Buckton, G., Dissado, L.A., Hill, R.M. and Newton, J.M.
The potential value of dielectric response measurements in the assessment of the wettability of powders (38) 1
Buendía, M.D.P., see Plá-Delfina, J.M. (37) 49
Bult, A., see Leeuwenkamp, O.R. (33) 1
Bundgaard, H. and Buur, A.
Prodrugs as drug delivery systems. 65. Hydrolysis of α-hydroxy- and α-acyloxy-*N*-benzoylglycine derivatives and implications for the design of prodrugs of NH-acidic compounds (37) 185
Bundgaard, H., Buur, A., Chang, S.-C. and Lee, V.H.L.
Prodrugs of timolol for improved ocular delivery: synthesis, hydrolysis kinetics and lipophilicity of various timolol esters (33) 15
Bundgaard, H., see Buur, A. (36) 41
Bundgaard, H., see Larsen, J.D. (37) 87
Bundgaard, H., see Mosher, G.L. (39) 113
Bundgaard, H., see Nielsen, N.M. (39) 75
Burgess, D.J., Davis, S.S. and Tomlinson, E.
Potential use of albumin microspheres as a drug delivery system. I. Preparation and in vitro release of steroids (39) 129
Burgess, D.J. and Carless, J.E.
Microelectrophoretic behaviour of gelatin and acacia complex coacervates and indomethacin microcapsules (32) 207
Busker, R.W., Van Henegouwen, G.M.J.B., Kwee, B.M.C. and Winkens, J.H.M.
Photobinding of flunitrazepam and its major photo-decomposition product *N*-desmethylflunitrazepam (36) 113
Buur, A. and Bundgaard, H.
Prodrugs of 5-fluorouracil. VIII. Improved rectal and oral delivery of 5-fluorouracil via various prodrugs. Structure–rectal absorption relationships (36) 41
Buur, A., see Bundgaard, H. (33) 15
Buur, A., see Bundgaard, H. (37) 185
Buxeraud, J., see Jambut-Absil, A.C. (35) 129
Bye, A., see Gilbert, J.C. (32) 223
Byron, P.R.
Predication of interfacial transfer kinetics. Reply to de Haan and Jansen (33) 269

Caldwell, L.J., see Itoh, T. (33) 265
Calvo, M.V., Lanao, J.M. and Domínguez-Gil, A.
Bioavailability of rectally administered naproxen (38) 117
Camber, O. and Edman, P.
Factors influencing the corneal permeability of prostaglandin $F_{2\alpha}$ and its isopropyl ester in vitro (37) 27
Camber, O. and Edman, P.
Influence of some preservatives on the corneal permeability of pilocarpine and dexamethasone, in vitro (39) 229
Carelli, V., Di Colo, G. and Nannipieri, E.
Factors in zero-order release of clonidine hydrochloride from monolithic polydimethylsiloxane matrices (35) 21
Carless, J.E., see Burgess, D.J. (32) 207
Carli, F., Colombo, I., Magarotto, L., Motta, A. and Torricelli, C.
Influence of polymer characteristics on drug loading into crospovidone (33) 115
Carstensen, J.T., see Ertel, K.D. (34) 179
Casabó, V.G., see Plá-Delfina, J.M. (37) 49
Castaño, A., see Navarro, A.S. (37) 113
Cavrini, V., see Di Pietra, A.M. (35) 13
Cavrini, V., see Nobile, L. (40) 85
Chang, C.-J., see Melethil, S. (31) 83
Chang, S.-C., see Bundgaard, H. (33) 15
Charman, W.N.A., Noguchi, T. and Stella, V.J.
An experimental system designed to study the in situ intestinal lymphatic transport of lipophilic drugs in anesthetized rats (33) 155
Charman, W.N.A. and Stella, V.J.
Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT (33) 165
Charman, W.N.A., Noguchi, T. and Stella, V.J.
Testing potential dosage form strategies for intestinal lymphatic drug transport: studies in the rat (33) 173
Charman, W.N.A. and Stella, V.J.
Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules (34) 175
Chaudry, I., see Sangekar, S. (35) 187
Chiang, C.-M. and Weiner, N.
Gastrointestinal uptake of liposomes. I. In vitro and in situ studies (37) 75
Chiang, C.-M. and Weiner, N.
Gastrointestinal uptake of liposomes. II. In vivo studies (40) 143
Chin, N.L.J., see Leeuwenkamp, O.R. (33) 1
Claessen, A., see Steerenberg, P.A. (40) 51
Clark, A.G., see Hardy, J.G. (31) 151
Clark, A.G., see Hardy, J.G. (37) 245
Clarke, S.W., see Newman, S.P. (36) 55
Colombo, I., see Carli, F. (33) 115
Conklin, J.D., see Mason, W.D. (36) 105
Conley, D., see Johnson, D.M. (31) 125
Coombes, R., see Jacobs, G.P. (32) 151
Corradeschi, F., see Bocci, V. (34) 111
Cotton, M.L., Wu, D.W. and Vadas, E.B.
Drug–excipient interaction study of enalapril maleate using thermal analysis and scanning electron microscopy (40) 129
Couarraze, G., see Dubernet, C. (35) 145
Couvreur, P., see Henry-Michelland, S. (35) 121
Couvreur, P., see Lenaerts, V. (39) 121
Crain-Denoyelle, A.M., see Heyman, M. (37) 33
Crommelin, D.J.A., see Fransen, G.J. (33) 27
Crommelin, D.J.A., see Jousma, H. (35) 263
Crommelin, D.J.A., see Talsma, H. (37) 171
Cutt, T., Fell, J.T., Rue, P.J. and Spring, M.S.
Granulation and compaction of a model system. I. Granule properties (33) 81
Cutt, T., Fell, J.T., Rue, P.J. and Spring, M.S.
Granulation and compaction of a model system. II. Stress relaxation (39) 157

Damgé, C., Aprahamian, M., Balboni, G., Hoeltzel, A., Andrieu, V. and Devissaguet, J.P.

Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug (36) 121
Darbord, J.-C. and Laizier, J.
A theoretical basis for choosing the dose in radiation sterilization of medical supplies (37) 1
Darbord, J.C., see Guyomard, S. (40) 173
D'Arcy, P.F., see McElnay, J.C. (31) 107
D'Arcy, P.F., see McElnay, J.C. (33) 261
D'Arcy, P.F., see McElnay, J.C. (36) 199
D'Arcy, P.F., see Yahya, A.M. (31) 65
D'Arcy, P.F., see Yahya, A.M. (34) 137
Davidsson, B., see Edman, P. (34) 225
Davies, M.C., see Gilbert, J.C. (40) 93
Davis, S.S., Hardy, J.G., Wilson, C.G., Feely, L.C. and Palin, K.J.
Gastrointestinal transit of a controlled release naproxen tablet formulation (32) 85
Davis, S.S., Illum, L. and Walker, I.M.
The in vivo evaluation of emulsion formulations administered intramuscularly (38) 133
Davis, S.S., Khosla, R., Wilson, C.G. and Washington, N.
Gastrointestinal transit of a controlled-release pellet formulation of tiaprofenic acid and the effect of food (35) 253
Davis, S.S., see Al-Khamis, K. (40) 111
Davis, S.S., see Burgess, D.J. (39) 129
Davis, S.S., see Douglas, S.J. (34) 145
Davis, S.S., see Farraj, N.F. (38) 39
Davis, S.S., see Hardy, J.G. (38) 103
Davis, S.S., see Washington, C. (39) 33
Davis, S.S., see Washington, N. (34) 105
Deasy, P.B., see Brophy, M.R. (37) 41
De Bolós, J., Galindo, C., Gallardo, M. and Pico, A.R.
Prediction of stability of cefazolin sodium in perfusion fluids (40) 175
Dechesne, J.-P. and Delattre, L.
A new enteric tablet of acetylsalicylic acid. II. Biopharmaceutical aspects (34) 259
Dechesne, J.-P.
A new enteric tablet of acetylsalicylic acid. I. Technological aspects (37) 203
De Groot, G., see Steerenberg, P.A. (40) 51
De Haan, P. and Lerk, C.F.
The megaloporous system: a novel principle for zero-order drug delivery I. In vitro and in vivo performance (31) 15
De Haan, P. and Lerk, C.F.
The megaloporous system: a novel principle for zero-order drug delivery. II. A model for the mechanism of drug delivery (34) 57
De Jong, W.H., see Steerenberg, P.A. (40) 51
Delattre, L., see Dechesne, J.-P. (34) 259
De Meere, A.L.J., Taylor, P.J., Grünbauer, H.J.M. and Tomlinson, E.
Local composition models in pharmaceutical chemistry. II. Differentiation of hydrophobic fragmental constants (31) 209
De Meere, A.L.J., see Grünbauer, H.J.M. (32) 187
Denyer, S.P., see Martin, R.J. (39) 23
Desager, J.-P., Meunier, M.S.H. and Harvengt, C.
Pharmacokinetics and disposition of nifedipine and acebutolol as a fixed combination or given separately after single and repeated dose in healthy subjects (31) 179
Desjeux, J.F., see Heyman, M. (37) 33
Devissaguet, J.P., see Damgé, C. (36) 121
Devleeschouwer, M.J., Boussard, P., Momin, P. and Dony, J.
Difference of *Pseudomonas aeruginosa* sensitivity to chloroxylenol according to the culture medium (32) 55
Devleeschouwer, M.J., see Boussard, P. (32) 91
Devleeschouwer, M.J., see Vincké, B.J. (32) 61
De Vries, H., see Van Henegouwen, G.M.J.B. (35) 259
Dick, C.F., Klassen, R.A. and Amidon, G.E.
Determination of the sensitivity of a tablet formulation to variations in excipient levels and processing conditions using optimization techniques (38) 23
Di Colo, G., see Carelli, V. (35) 21
Digenis, G., see Sangekar, S. (35) 187
Di Pietra, A.M., Cavrini, V. and Raggi, M.A.
Determination of benzaldehyde traces in benzyl alcohol by liquid chromatography (HPLC) and derivative UV spectrophotometry (35) 13
Di Pietra, A.M., see Nobile, L. (40) 85
Dispensing, , see Vromans, H. (39) 207
Dissado, L.A., see Buckton, G. (38) 1
Djurić, M., Jovanović, M. and Djurić, Z.
Influence of drug amount and dioctyl sodium sulfosuccinate on dissolution of propyphenazone tablets (37) 179
Djurić, Z., see Djurić, M. (37) 179
Djurić, Z., see Rakić, R. (39) 47
D'Mello, A., see D'Souza, M. (31) 165
Dobrilovic, L., see Jacobs, G.P. (32) 151
Doherty, C. and York, P.
Mechanisms of dissolution of frusemide/PVP solid dispersions (34) 197
Domínguez-Gil, A., see Calvo, M.V. (38) 117
Dony, J., see Boussard, P. (32) 91
Dony, J., see Devleeschouwer, M.J. (32) 55
Dony, J., see Vincké, B.J. (32) 61
Dor, P., see Benita, S. (33) 71
Douglas, S.J., Davis, S.S. and Illum, L.
Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits (34) 145
Dowse, R., Haigh, J.M. and Kanfer, I.
Pharmacokinetics of phenylpropanolamine in humans after a single-dose study (39) 141
Driebergen, R.J., see Beijnen, J.H. (34) 247
Droin, A., see Eddine, A. (32) 143
D'Souza, M., Venkataramanan, R., D'Mello, A. and Niphadkar, P.
An alternative prodrug approach for reducing presystemic metabolism of drugs (31) 165
Dubernet, C., Benoit, J.P., Couarraze, G. and Duchêne, D.
Microencapsulation of nitrofurantoin in poly(ε-caprolactone): tableting and in vitro release studies (35) 145

Dubois, J.G., Hanocq, M. and Atassi, G.
Extraction and assay of daunorubicin and its metabolites from neoplastic tissue (35) 219
Duchateau, G.S.M.J.E., Zuidema, J. and Basseleur, S.W.J.
Influence of some surface-active agents on nasal absorption in rabbits (39) 87
Duchateau, G.S.M.J.E., Zuidema, J. and Merkus, F.W.H.M.
Bile salts and intranasal drug absorption (31) 193
Duchateau, G.S.M.J.E., Zuidema, J., Albers, W.M. and Merkus, F.W.H.M.
Nasal absorption of alprenolol and metoprolol (34) 131
Duchateau, G.S.M.J.E., Zuidema, J., Hermens, W.A.J.J. and Merkus, F.W.H.M.
In vitro ciliotoxicity of propranolol isomers (31) 275
Duchêne, D., see Dubernet, C. (35) 145
Duchêne, D., see Ponchel, G. (38) 65
Du Plessis, J., Tiedt, L.R., Van Wyk, C.J. and Ackermann, C.
A new transmission electron microscope method for the determination of particle size in parenteral fat emulsions (34) 173

Eddine, A., Droin, A., Taverdet, J.L. and Vergnaud, J.M.
Effect of pH on drug release between sodium salicylate–Eudragit compound and gastric liquid: modelling of the process (32) 143
Edgar, P.J., see Ford, J.L. (40) 223
Edman, P., Artursson, P., Björk, E. and Davidsson, B.
Immobilized L-asparaginase-L-glutaminase from *Acinetobacter glutaminasificans* in microspheres: some properties in vivo and in an extracorporeal system (34) 225
Edman, P., see Camber, O. (37) 27
Edman, P., see Camber, O. (39) 229
Edwards, H.E., see Menzies, A.R. (37) 65
El-Gendy, G.A., Terada, K., Yamamoto, K. and Nakai, Y.
Molecular behavior, dissolution characteristics and chemical stability of aspirin in the ground mixture and in the inclusion complex with di-O-methyl-β-cyclodextrin (31) 25
El-Hinnawi, M.A. and Najib, N.M.
Ibuprofen–polyvinylpyrrolidone dispersions. Proton nuclear magnetic resonance and infrared studies (37) 175
El-Hofy, S.A., see Gouda, M.W. (37) 277
El-Kirsh, T.A., see El-Samaligy, M.S. (31) 137
El-Mahrouk, G.M., see El-Samaligy, M.S. (31) 137
El-Samaligy, M.S., El-Mahrouk, G.M. and El-Kirsh, T.A.
Adsorption–desorption effect of microcrystalline cellulose on ampicillin and amoxycillin (31) 137
Elliott, D.S., see McElnay, J.C. (36) 199
Ertel, K.D. and Carstensen, J.T.
Validity of the steady-state assumption in in vitro liposomal absorption enhancement modeling: the free solute mechanism as an example (34) 179
Evans, D.F., see Hardy, J.G. (37) 245

Falch, E., see Mosher, G.L. (39) 113
Farah, N., Bouzon, J., Rollet, M., Taverdet, J.L. and Vergnaud, J.M.
'Dry emulsion' — a sustained release form: modelling of drug transfers in liquids (36) 81
Farraj, N.F., Davis, S.S., Parr, G.D. and Withington, R.
A new intramuscular formulation of rifamycin SV (38) 39
Fassihi, A.R. and Parker, M.S.
Formulation effects on capping tendencies (31) 271
Fassihi, A.R. and Persicaner, P.H.R.
Solid state interaction of bromazepam with polyvinylpyrrolidone in the presence of moisture (37) 167
Fassihi, A.R.
Continuous matrix formation for controlled drug release: compression of isotropic polymeric system (34) 169
Fassihi, A.R.
Kinetics of drug release from solid matrices: effect of compaction pressure (37) 119
Fassihi, A.R.
Mechanisms of disintegration and compactibility of disintegrants in a direct compression system (32) 93
Fawzi, M.B., see Ghebre-Sellassie, I. (31) 43
Fawzi, M.B., see Ghebre-Sellassie, I. (37) 211
Feely, L.C., see Davis, S.S. (32) 85
Feely, L.C., see Hardy, J.G. (38) 103
Feldkamp, J.R., see Morefield, E.M. (34) 263
Fell, J.T., see Cutt, T. (33) 81
Fell, J.T., see Cutt, T. (39) 157
Femi-Oyewo, M.N.
Granulations with surfactants: effects on pasting (40) 73
Firestone, B.A., see Benjamin, E.J. (35) 73
Fitzgerald, P., Hadgraft, J., Kreuter, J. and Wilson, C.G.
A γ-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles (40) 81
Flanders, P., see Staniforth, J.N. (31) 277
Florence, A.T., see Al-Dujaili, H. (34) 67
Florence, A.T., see Al-Dujaili, H. (34) 75
Florence, A.T., see Law, T.K. (33) 65
Florida, U., see Waranis, R.P. (36) 211
Flynn, G.L., see Ackermann, C. (36) 61
Flynn, G.L., see Ackermann, C. (36) 67
Fokkens, R.H., see Beijnen, J.H. (32) 111
Ford, J.L., Rubinstein, M.H., McCaul, F., Hogan, J.E. and Edgar, P.J.
Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropylmethylcellulose matrix tablets (40) 223
Fort, J.J. and Mitra, A.K.
Physicochemical properties and chromatographic behavior of a homologous series of methotrexate-α,γ-dialkyl ester prodrugs (36) 7
Fortier, M., see Heyman, M. (37) 33
Fransen, G.J., Salemink, P.J.M. and Crommelin, D.J.A.
Critical parameters in freezing of liposomes (33) 27
Friedman, M., see Hussein, Z. (37) 97
Fujimoto, T., see Nishihata, T. (33) 181
Fukuda, T., Gomita, Y., Furuno, K. and Araki, Y.
Determination of antiepileptic drug concentrations in animal blood by the SLFIA method (36) 1
Fukui, H., Murakami, M., Takada, K. and Muranishi, S.
Combinative promotion effect of Azone and fusogenic fatty acid on the large intestinal absorption in rat (31) 239

Funaki, T., Furuta, S. and Kaneniwa, N.
Discontinuous absorption property of cimetidine (31) 119
Funaki, T., see Kaneniwa, N. (31) 33
Funaki, T., see Kaneniwa, N. (34) 231
Funaki, T., see Kaneniwa, N. (34) 9
Furr, J.R., see Russell, A.D. (34) 115
Furr, J.R., see Russell, A.D. (35) 227
Furr, J.R., see Russell, A.D. (36) 191
Furr, J.R., see Shaker, L.A. (34) 51
Furuno, K., see Fukuda, T. (36) 1
Furuta, S., see Funaki, T. (31) 119
Furuta, S., see Kaneniwa, N. (31) 33
Fyhr, P. and Brodin, A.
A preformulation study on the kinetics of pralidoxime chloride in concentrated acidic solution (40) 157
Fyhr, P., Nicklasson, M., Gunnvald, K. and Brodin, A.
A preformulation study on the kinetics of HI-6 in concentrated solution (40) 193

Gaber, M., see Moustafa, M.A. (34) 207
Gadalla, M.A.F., Ghaly, G.M. and Samaha, M.W.
The effect of the composition of binary systems on the solubility and solubility parameter estimation of nalidixic and salicylic acids (38) 71
Gainesville, , see Waranis, R.P. (36) 211
Galindo, C., see De Bolós, J. (40) 175
Gallardo, M., see De Bolós, J. (40) 175
Gamst, O.N., see Hardy, J.G. (37) 245
Gardner, M.J. and Jusko, W.J.
Effects of oral contraceptives and tobacco use on the metabolic pathways of theophylline (33) 55
Gassim, A.E.H., Takla, P.G. and James, K.C.
Polymorphism and possible intramolecular bonding in benperidol (34) 23
Gebre-Mariam, T., see Armstrong, N.A. (34) 125
Genetet, B., see Rolland, A. (39) 173
Ghaly, G.M., see Gadalla, M.A.F. (38) 71
Ghebre-Sellassie, I., Gordon, R.H., Middleton, D.L., Nesbitt, R.U. and Fawzi, M.B.
A unique application and characterization of Eudragit E 30 D film coatings in sustained release formulations (31) 43
Ghebre-Sellassie, I., Gordon, R.H., Nesbitt, R.U. and Fawzi, M.B.
Evaluation of acrylic-based modified-release film coatings (37) 211
Giannaccini, B., see Saettone, M.F. (31) 261
Gilbert, J.C., Hadgraft, J., Bye, A. and Brookes, L.G.
Drug release from Pluronic F-127 gels (32) 223
Gilbert, J.C., Washington, C., Davies, M.C. and Hadgraft, J.
The behaviour of Pluronic F127 in aqueous solution studied using fluorescent probes (40) 93
Gilbert, P., see Al-Adham, I.S.I. (34) 45
Gipps, E.M., Groscurth, P., Kreuter, J. and Speiser, P.P.
The effects of polyalkylcyanoacrylate nanoparticles on human normal and malignant mesenchymal cells in vitro (40) 23

Go, J. and Grant, D.J.W.
Locating the impurity in doped crystals using isotopic double labelling and a column "flow-through" dissolution cell: adipic acid doped with oleic acid (36) 17
Gogate, U.S. and Repta, A.J.
N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. II. Esterase-catalysed release of parent amines from model prodrugs (40) 249
Gogate, U.S., Repta, A.J. and Alexander, J.
N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I. Kinetics and mechanism of degradation in aqueous solutions (40) 235
Gomita, Y., see Fukuda, T. (36) 1
Gooch, C.A., see Beezer, A.E. (38) 251
Gordon, R.H., see Ghebre-Sellassie, I. (31) 43
Gordon, R.H., see Ghebre-Sellassie, I. (37) 211
Gorman, S.P., see McCafferty, D.F. (38) 59
Gouda, M.W., Babhair, S.A., Al-Angary, A.A., El-Hofy, S.A. and Mahrous, G.M.
Effect of dosage form, food, and an anticholinergic drug on the bioavailability of sulpiride (37) 277
Gouda, M.W., see Moustafa, M.A. (34) 207
Gould, P.L., Holland, S.J. and Tighe, B.J.
Polymers for biodegradable medical devices. IV. Hydroxybutyrate–valerate copolymers as non-disintegrating matrices for controlled-release oral dosage forms (38) 231
Gould, P.L.
Salt selection for basic drugs (33) 201
Gould, P.L., see Reid, A.S. (40) 181
Gould, P.L., see Young, C. (40) 187
Goury, V., see Guyomard, S. (40) 173
Graffner, C., see Nicklasson, M. (40) 165
Grant, D.J.W., see Go, J. (36) 17
Grant, D.J.W., see Pikal, M.J. (39) 243
Grant, D.J.W., see Vachon, M.G. (40) 1
Green, P.G. and Hadgraft, J.
Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid (37) 251
Gröning, R.
Electrophoretically controlled dermal or transdermal application systems with electronic indicators (36) 37
Groscurth, P., see Gipps, E.M. (40) 23
Grünbauer, H.J.M., De Meere, A.L.J. and Van Rooij, H.H.
Local composition models in pharmaceutical chemistry. III. Prediction of drug solubility in binary aqueous mixtures (32) 187
Grünbauer, H.J.M., see De Meere, A.L.J. (31) 209
Guiducci, A., see Saettone, M.F. (31) 261
Gumbleton, M., Nicholls, P.J. and Taylor, G.
Urethane anaesthesia: altered pharmacokinetics of the renally eliminated organic anion *p*-aminohippuric acid (38) 261
Gummer, C.L., Hinz, R.S. and Maibach, H.I.
The skin penetration cell: a design update (40) 101
Gunnvald, K., see Fyhr, P. (40) 193

Gupta, P.K., Hung, C.T. and Perrier, D.G.
Albumin microspheres. I. Release characteristics of adriamycin (33) 137
Gupta, P.K., Hung, C.T. and Perrier, D.G.
Albumin microspheres. II. Effect of stabilization temperature on the release of adriamycin (33) 147
Gurny, R., see Harmia, T. (33) 187
Guy, R.H. and Hadgraft, J.
Interpretation and prediction of the kinetics of transdermal drug delivery: oestradiol, hyoscine and timolol (32) 159
Guyomard, S., Goury, V., Laizier, J. and Darbord, J.C.
Defining of the pyrogenic assurance level (PAL) of irradiated medical devices (40) 173

Haas, C., see Leuenberger, H. (38) 109
Habib, F.S., see Kassem, M.A. (32) 47
Hadgraft, J. and Ridout, G.
Development of model membranes for percutaneous absorption measurements. I. Isopropyl myristate (39) 149
Hadgraft, J., Walters, K.A. and Wotton, P.K.
Facilitated percutaneous absorption: a comparison and evaluation of two in vitro models (32) 257
Hadgraft, J., see Al-Khamis, K. (40) 111
Hadgraft, J., see Fitzgerald, P. (40) 81
Hadgraft, J., see Gilbert, J.C. (32) 223
Hadgraft, J., see Gilbert, J.C. (40) 93
Hadgraft, J., see Green, P.G. (37) 251
Hadgraft, J., see Guy, R.H. (32) 159
Hadgraft, J., see Martin, R.J. (39) 23
Haigh, J.M., see Dowse, R. (39) 141
Hailey, F.J., see Mason, W.D. (36) 105
Hamaguchi, N., see Yoshimura, Y. (38) 179
Hanocq, M., see Dubois, J.G. (35) 219
Hansen, S.H.
HPLC assay of the opiates in opium and cough mixtures using dynamically modified silica and UV absorbance, fluorescence and electrochemical detection (32) 7
Hardy, J.G., Evans, D.F., Zaki, I., Clark, A.G., Tønnesen, H.H. and Gamst, O.N.
Evaluation of an enteric coated naproxen tablet using gamma scintigraphy and pH monitoring (37) 245
Hardy, J.G., Feely, L.C., Wood, E. and Davis, S.S.
The application of γ-scintigraphy for the evaluation of the relative spreading of suppository bases in rectal hard gelatin capsules (38) 103
Hardy, J.G., Lee, S.W., Clark, A.G. and Reynolds, J.R.
Enema volume and spreading (31) 151
Hardy, J.G., see Davis, S.S. (32) 85
Hardy, J.G., see O'Reilly, S. (34) 213
Hardy, J.G., see Wilson, C.G. (38) 221
Harland, R., see McElnay, J.C. (40) 105
Harmia, T., Kreuter, J., Speiser, P., Boye, T., Gurny, R. and Kubis, A.
Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles (33) 187
Harmia, T., Speiser, P. and Kreuter, J.
Optimization of pilocarpine loading onto nanoparticles by sorption procedures (33) 45
Harrison, P.J., Newton, J.M. and Rowe, R.C.
The application of capillary rheometry to the extrusion of wet powder masses (35) 235
Hart, J.P., see Staniforth, J.N. (40) 267
Harvengt, C., see Desager, J.-P. (31) 179
Hashida, M., see Higaki, K. (36) 131
Hashida, M., see Sasaki, H. (36) 147
Hashida, M., see Takakura, Y. (37) 135
Hashida, M., see Takakura, Y. (37) 145
Hashida, M., see Yamamoto, A. (39) 255
Hashim, H. and Li Wan Po, A.
Improving the release characteristics of water-soluble drugs from hydrophilic sustained release matrices by in situ gas generation (35) 201
Hayashi, M., see Kajii, H. (33) 253
Heikkilä, T., see Laine, E. (38) 33
Hem, S.L., see Morefield, E.M. (34) 263
Hemgesberg, E., see Loth, H. (32) 265
Henry-Michelland, S., Alonso, M.J., Andremont, A., Maincen, P., Sauzières, J. and Couvreur, P.
Attachment of antibiotics to nanoparticles: preparation, drug-release and antimicrobial activity in vitro (35) 121
Hermens, W.A.J.J., see Duchateau, G.S.M.J.E. (31) 275
Herrador, M.A., see Asuero, A.G. (34) 81
Hersey, J.A., see Lai, F.K.Y. (36) 157
Heyman, M., Bonfils, A., Fortier, M., Crain-Denoyelle, A.M., Smets, P. and Desjeux, J.F.
Intestinal absorption of RU 41740, an immunomodulating compound extracted from *Klebsiella pneumoniae*, across duodenal epithelium and Peyer's patches of the rabbit (37) 33
Higaki, K., Kishimoto, I., Komatsu, H., Hashida, M. and Sezaki, H.
Effect of medium-chain glycerides on the intestinal absorption and the hepatobiliary transport of Phenol red (36) 131
Higashi, Y., see Kadir, S. (33) 235
Higashi, Y., see Kadir, S. (40) 257
Higuchi, T., see Itoh, T. (33) 265
Higuchi, T., see Nishihata, T. (31) 185
Higuchi, W.I., see Morimoto, Y. (32) 31
Hill, R.A. and Snider, B.G.
A widely applicable automated sampling apparatus for dissolution testing (36) 175
Hill, R.M., see Buckton, G. (38) 1
Hilton, J.E. and Summers, M.P.
A comparison between the in vivo serum levels and in vitro dissolution of indomethacin–polymer dispersion systems (33) 219
Hilton, J.E. and Summers, M.P.
The effect of polyvinylpyrrolidones on intestinal ulceration caused by indomethacin (32) 13
Hilton, J.E. and Summers, M.P.
The effect of wetting agents on the dissolution of indomethacin solid dispersion systems (31) 157

Hinz, R.S., see Gummer, C.L. (40) 101
Hirayama, F., Kurihara, M. and Uekama, K.
Improvement of chemical instability of prostacyclin in aqueous solution by complexation with methylated cyclodextrins (35) 193
Hirayama, F., see Hoshino, T. (38) 265
Hirayama, F., see Kikuchi, M. (38) 191
Hiura, M., see Kaneniwa, N. (34) 9
Hoelgaard, A., see Johansen, M. (32) 199
Hoeltzel, A., see Damgé, C. (36) 121
Hogan, J.E., see Ford, J.L. (40) 223
Holland, S.J., see Gould, P.L. (38) 231
Horie, T., see Kajii, H. (33) 253
Hoshino, T., Ishida, K., Irie, T., Hirayama, F. and Uekama, K.
Alleviation in protriptyline-photosensitized skin irritation by di-*O*-methyl-*β*-cyclodextrin complexation (38) 265
Hosoya, K.-i., see Morimoto, Y. (32) 31
Howard, J.R., see Waring, M.J. (36) 29
Howard, J.R., see Waring, M.J. (40) 15
Howe, K.D., see Rosen, A. (32) 171
Hung, C.T., see Gupta, P.K. (33) 137
Hung, C.T., see Gupta, P.K. (33) 147
Hunt, C.A., see Schreier, H. (37) 233
Hunter, W.H., see Beezer, A.E. (38) 251
Hurlé, A.D.-G., see Navarro, A.S. (37) 113
Hussain, M.A., Aungst, B.J., Kearney, A. and Shefter, E.
Buccal and oral bioavailability of naloxone and naltrexone in rats (36) 127
Hussein, Z., Bialer, M., Friedman, M. and Raz, I.
Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans (37) 97
Huu-Phuoc, N., Nam-Tran, H., Buchmann, M. and Kesselring, U.W.
Experimentally optimized determination of the partial and total cohesion parameters of an insoluble polymer (microcrystalline cellulose) by gas–solid chromatography (34) 217

Ikeda, C., see Yamaguchi, T. (37) 127
Illum, L., Jørgensen, H., Bisgaard, H., Krogsgaard, O. and Rossing, N.
Bioadhesive microspheres as a potential nasal drug delivery system (39) 189
Illum, L., see Davis, S.S. (38) 133
Illum, L., see Douglas, S.J. (34) 145
Inagaki, H., see Nishihata, T. (34) 157
Inagaki, H., see Nishihata, T. (38) 83
Ingani, H.M., Timmermans, J. and Moës, A.J.
Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit (35) 157
Inoue, M., see Kokubo, H. (35) 181
Irie, T., see Hoshino, T. (38) 265
Irwin, V.P., Quigley, J.M. and Timoney, R.F.
Quantitative relationships between in vitro antibacterial activities of cephalosporins and their *n*-octanol/water partition coefficients (34) 241
Irwin, W.J., see Liak, T.L. (36) 233
Ishida, K., see Hoshino, T. (38) 265
Ishida, T., see Kokubo, H. (35) 181
Ishii, M., see Ando, H. (34) 153
Islasse, M., see Aiache, J.-M. (39) 235
Ismail, F.A., Khalafallah, N. and Khalil, S.A.
Adsorption of ketoprofen and bumadizone calcium on aluminium-containing antacids and its effect on ketoprofen bioavailability in man (34) 189
Ismail, S. and Morton, D.J.
Ophthalmic uptake of chloramphenicol from proprietary preparations using an in vitro method of evaluation (37) 11
Itiola, O.A. and Pilpel, N.
Tableting characteristics of metronidazole formulations (31) 99
Itoh, T., Higuchi, T. and Caldwell, L.J.
Dynamic friction of some film coatings on rat stomach mucosa in vitro – effect of pH (33) 265
Iveson, S.R., see Staniforth, J.N. (31) 145

Jachowicz, R.
Dissolution rates of partially water-soluble drugs from solid dispersion systems. I. Prednisolone (35) 1
Jachowicz, R.
Dissolution rates of partially water-soluble drugs from solid dispersion systems. II. Phenytoin (35) 7
Jackson, I.M., see Rubinstein, M.H. (36) 99
Jacobs, G.P., Dobrilovic, L., Coombes, R. and Raghavan, N.
HPLC analysis of γ-irradiated *β*-lactam antibiotics (32) 151
Jalal, I., see Shaheen, O. (38) 123
Jambut-Absil, A.C., Buxeraud, J., Lagorce, J.F. and Raby, C.
Charge transfer complexes of drugs with iodine investigation by UV/visible spectroscopy (35) 129
James, K.C., see Armstrong, N.A. (34) 125
James, K.C., see Gassim, A.E.H. (34) 23
Jay, M., see Parr, A. (32) 251
Jensen, M.M., see Kipp, J.E. (34) 1
Jetzer, W.E.
Compaction characteristics of binary mixtures (31) 201
Jeyanthi, R. and Rao, K.P.
Preparation of gelatin microspheres of bleomycin (35) 177
Johansen, M., Møllgaard, B., Wotton, P.K., Larsen, C. and Hoelgaard, A.
In vitro evaluation of dermal prodrug delivery — transport and bioconversion of a series of aliphatic esters of metronidazole (32) 199
Johansen, M., see Larsen, C. (35) 39
Johnson, D.M., Pritchard, R.A., Taylor, W.F., Conley, D., Zuniga, G. and McGreevy, K.G.
Degradation of the LH-RH analog nafarelin acetate in aqueous solution (31) 125
Jones, S.P. and Parr, G.D.
Polarographic detection of beta-cyclodextrin inclusion complexes (33) 105
Jones, S.P. and Parr, G.D.
The acetotoluides as models for studying cyclodextrin inclusion complexes (36) 223

Joosten, J.G.H., see Jousma, H. (35) 263
Jørgensen, H., see Illum, L. (39) 189
Jousma, H., Talsma, H., Spies, F., Joosten, J.G.H., Junginger, H.E. and Crommelin, D.J.A.
Characterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayers (35) 263
Jousma, H., see Talsma, H. (37) 171
Jovanović, M., see Djurić, M. (37) 179
Jovanović, M., see Rakić, R. (39) 47
Judy, C.L., see Acree, Jr., W.E. (31) 225
Junginger, H.E., see Jousma, H. (35) 263
Jusko, W.J., see Gardner, M.J. (33) 55

Kadir, S., Murakami, T., Higashi, Y. and Yata, N.
Gastrointestinal absorption of griseofulvin from liquid organic acids and esters in rats (33) 235
Kadir, S., Nitta, C., Koga, I., Murakami, T., Higashi, Y. and Yata, N.
Possible factors behind the enhanced gastrointestinal absorption of griseofulvin from liquid organic acid ester solutions in rats (40) 257
Kahela, P., see Laine, E. (38) 33
Kaiser, E., see Waser, P.G. (39) 213
Kajii, H., Horie, T., Hayashi, M. and Awazu, S.
Effects of sodium salicylate and caprylate as adjuvants of drug absorption on isolated rat small intestinal epithelial cells (33) 253
Kamada, A., see Nishihata, T. (33) 181
Kamada, A., see Nishihata, T. (34) 157
Kamada, A., see Nishihata, T. (38) 83
Kamide, S., see Nishihata, T. (33) 181
Kaneniwa, N., Funaki, T. and Hiura, M.
Estimation of the absorption rate constant for a drug subject to non-linear elimination: comparison on non-linear regression and the C_{max}, T_{max} approach (34) 9
Kaneniwa, N., Funaki, T., Furuta, S. and Watari, N.
Application of the Pidgeon-Pitlick method for calculation of the absorption rate constant of drugs whose disposition can be described by the two-compartment open model (31) 33
Kaneniwa, N., Watari, N. and Funaki, T.
Use of fluorescence HPLC for determining extrarenal creatinine clearance in rats (34) 231
Kaneniwa, N., see Funaki, T. (31) 119
Kanfer, I., see Dowse, R. (39) 141
Kantelip, J.-P., see Aiache, J.-M. (39) 235
Kaplan, J.E., see Schreier, H. (37) 233
Karjalainen, P., see Vidgren, M.T. (37) 239
Karjalainen, P., see Vidgren, M.T. (39) 101
Karjalainen, P., see Vidgren, M.T. (39) 107
Kärkkäinen, A., see Vidgren, M.T. (37) 239
Kärkkäinen, A., see Vidgren, M.T. (39) 101
Kärkkäinen, A., see Vidgren, M.T. (39) 107
Karlsen, J., see Tønnesen, H.H. (38) 247
Kassem, M.A., Attia, M.A., Habib, F.S. and Mohamed, A.A.
Activity of ophthalmic gels of betamethasone and phenylephrine hydrochloride in the rabbit's eye (32) 47
Kaufmann, B.G., see Moolenaar, F. (33) 249
Kawamori, R., see Nishihata, T. (34) 157
Kawamori, R., see Nishihata, T. (38) 83
Kawaratani, T., see Yamamoto, A. (39) 255
Kearney, A., see Hussain, M.A. (36) 127
Kearney, P. and Marriott, C.
The effects of mucus glycoproteins on the bioavailability of tetracycline. II. Binding (35) 211
Kearney, P. and Marriott, C.
The effects of mucus glycoproteins on the bioavailability of tetracycline. III. Everted gut studies (38) 211
Keigami, M., see Nishihata, T. (33) 181
Kennedy, T.A., see McElnay, J.C. (40) 105
Kennerley, J., see Wilson, C.G. (40) 119
Kerr, B., see McElnay, J.C. (33) 195
Kesselring, U.W., see Huu-Phuoc, N. (34) 217
Khalafallah, N., see Ismail, F.A. (34) 189
Khalil, S.A., see Ismail, F.A. (34) 189
Khosla, R., see Davis, S.S. (35) 253
Kikuchi, M., Hirayama, F. and Uekama, K.
Improvement of oral and rectal bioavailabilities of carmofur by methylated β-cyclodextrin complexations (38) 191
Kim, S., see Nishihata, T. (31) 185
Kim, S.W., see Lee, S.J. (39) 59
Kipp, J.E., Jensen, M.M., Kronholm, K. and McHalsky, M.
Automated liquid chromatography for non-isothermal kinetic studies (34) 1
Kishimoto, I., see Higaki, K. (36) 131
Kitajima, M., see Takakura, Y. (37) 135
Klassen, R.A., see Dick, C.F. (38) 23
Koch, S.A.M. and Sloan, K.B.
N-Mannich base derivatives of 5-fluorocytosine: a prodrug approach to improve topical delivery (35) 243
Koga, I., see Kadir, S. (40) 257
Koh, G.-L. and Tucker, I.G.
Variability in the phenol–sulphuric acid assay for sodium carboxymethylcellulose (34) 183
Kohli, R., Archer, W.I. and Li Wan Po, A.
Laser velocimetry for the non-invasive assessment of the percutaneous absorption of nicotinates (36) 91
Kokubo, H., Morimoto, K., Ishida, T., Inoue, M. and Morisaka, K.
Bioavailability and inhibitory effect for stress ulcer of cimetidine polymorphs in rats (35) 181
Komatsu, H., see Higaki, K. (36) 131
Kou, F.Y., see Law, S.L. (32) 237
Koupparis, M., see Macheras, P. (33) 125
Koupparis, M., see Macheras, P. (36) 73
Kouta, H.I., see Moustafa, M.A. (36) 187
Kreuter, J., see Fitzgerald, P. (40) 81
Kreuter, J., see Gipps, E.M. (40) 23
Kreuter, J., see Harmia, T. (33) 187
Kreuter, J., see Harmia, T. (33) 45

Kreuter, J., see Waser, P.G. (39) 213
Kristensen, A., see Alderborn, G. (37) 155
Krogsgaard, O., see Illum, L. (39) 189
Kronholm, K., see Kipp, J.E. (34) 1
Kubis, A., see Harmia, T. (33) 187
Kulvanich, P. and Stewart, P.J.
An evaluation of the air stream Faraday cage in the electrostatic charge measurement of interactive drug systems (36) 243
Kulvanich, P. and Stewart, P.J.
Correlation between total adhesion and charge decay of a model interactive system during storage (39) 51
Kulvanich, P. and Stewart, P.J.
Fundamental considerations in the measurement of adhesional forces between particles using the centrifuge method (35) 111
Kurihara-Bergstrom, T., see Lee, S.J. (39) 59
Kurihara, M., see Hirayama, F. (35) 193
Kussendrager, K.D., see Vromans, H. (39) 201
Kussendrager, K.D., see Vromans, H. (39) 207
Kwee, B.M.C., see Busker, R.W. (36) 113
Kwon, K. and Bourne, D.W.A.
Physiological pharmacokinetic model for the distribution and elimination of tenoxicam (37) 219

Laakso, T. and Smedsrød, B.
Cellular distribution in rat liver of intravenously administered polyacryl starch and chondroitin sulfate microparticles (36) 253
Laakso, T., see Stjärnkvist, P. (40) 215
Lagorce, J.F., see Jambut-Absil, A.C. (35) 129
Lai, F.K.Y. and Hersey, J.A.
Simulated ordered powder mixture (36) 157
Laine, E., Kahela, P., Rajala, R., Heikkilä, T., Saarnivaara, K. and Piippo, I.
Crystal forms and bioavailability of erythromycin (38) 33
Laizier, J., see Darbord, J.-C. (37) 1
Laizier, J., see Guyomard, S. (40) 173
Lanao, J.M., see Calvo, M.V. (38) 117
Lanao, J.M., see Navarro, A.S. (37) 113
Lång, P.O., see Alderborn, G. (37) 155
Larsen, C. and Johansen, M.
Macromolecular prodrugs IV. Kinetics of hydrolysis of metronidazole monosuccinate dextran ester conjugates in aqueous solution and in plasma — sequential release of metronidazole from the conjugates at physiological pH (35) 39
Larsen, C., see Johansen, M. (32) 199
Larsen, C., see Mosher, G.L. (39) 113
Larsen, J.D. and Bundgaard, H.
Prodrug forms for the sulfonamide group. I. Evaluation of *N*-acyl derivatives, *N*-sulfonylamidines, *N*-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives (37) 87
Launchbury, A.P., see Murphy, A. (38) 257
Launchbury, A.P., see Woolfson, A.D. (34) 17
Launchbury, A.P., see McCafferty, D.F. (31) 9
Law, S.L., Lo, W.Y., Pai, S.H., Teh, G.W. and Kou, F.Y.
The adsorption of bovine serum albumin by liposomes (32) 237
Law, T.K., Florence, A.T. and Whateley, T.L.
Some chemically modified poloxamer hydrogels: controlled release of prostaglandin-E_2 and testosterone (33) 65
Lee, S.J., Kurihara-Bergstrom, T. and Kim, S.W.
Ion-paired drug diffusion through polymer membranes (39) 59
Lee, S.W., see Hardy, J.G. (31) 151
Lee, V.H.L., see Bundgaard, H. (33) 15
Leeuwenkamp, O.R., Chin, N.L.J., Van der Mark, E.J., Van Bennekom, W.P. and Bult, A.
In vitro degradation of nitroprusside in relation to in vivo decomposition and mechanism of action (33) 1
Lenaerts, V., Triqueneaux, C., Quarton, M., Rieg-Falson, F. and Couvreur, P.
Temperature-dependent rheological behavior of Pluronic F-127 aqueous solutions (39) 121
Lencioni, E., see Bocci, V. (34) 111
Lerk, C.F., see De Haan, P. (31) 15
Lerk, C.F., see De Haan, P. (34) 57
Lerk, C.F., see Vromans, H. (35) 29
Lerk, C.F., see Vromans, H. (39) 201
Lerk, C.F., see Vromans, H. (39) 207
Leuenberger, H., Rohera, B.D. and Haas, C.
Percolation theory – a novel approach to solid dosage form design (38) 109
Le Verge, R., see Rolland, A. (39) 173
Liak, T.L., Li Wan Po, A. and Irwin, W.J.
The effects of drug therapy on urinary pH — excipient effects and bioactivation of methenamine (36) 233
Lima, M.C.P., see Beezer, A.E. (38) 251
Lin, L.H., see Benjamin, E.J. (35) 73
Lindberg, J., see Nicklasson, M. (37) 195
Lindley, M., see Patel, C.I. (39) 93
Linert, W., see Repond, C. (38) 47
Liversidge, G.G., see Nishihata, T. (31) 185
Li Wan Po, A., see Hashim, H. (35) 201
Li Wan Po, A., see Kohli, R. (36) 91
Li Wan Po, A., see Liak, T.L. (36) 233
Lo, W.Y., see Law, S.L. (32) 237
Loth, H. and Hemgesberg, E.
Properties and dissolution of drugs micronized by crystallization from supercritical gases (32) 265
Lovrecich, M. and Rubessa, F.
Effect of loading parameters on theophylline release from polystyrene beads (40) 63

McCafferty, D.F., Woolfson, A.D., Gorman, S.P. and Anderson, L.
Chemical behaviour of noxythiolin in biological fluids (38) 59
McCafferty, D.F., see Woolfson, A.D. (34) 17
McCafferty, D.F., Woolfson, A.D. and Launchbury, A.P.
Stability of temazepam in parenteral formulations (31) 9
McCaul, F., see Ford, J.L. (40) 223

McCornack, J., see Bodor, N. (35) 47
McElnay, J.C. and D'Arcy, P.F.
Aluminium content of infusion and irrigation fluids (33) 261
McElnay, J.C., Elliott, D.S. and D'Arcy, P.F.
Binding of human insulin to burette administration sets (36) 199
McElnay, J.C., Kennedy, T.A. and Harland, R.
The influence of ultrasound on the percutaneous absorption of fluocinolone acetonide (40) 105
McElnay, J.C., Sidahmed, A.M. and D'Arcy, P.F.
Experimental modelling of drug absorption and drug absorption interactions (31) 107
McElnay, J.C., Taggart, A.J., Kerr, B. and Passmore, P.
Comparison of serum indomethacin profiles after rectal administration of two brands of indomethacin suppositories in healthy volunteer subjects (33) 195
McElnay, J.C., see Yahya, A.M. (31) 65
McElnay, J.C., see Yahya, A.M. (34) 137
McGinity, J.W., see Walkow, J.C. (35) 103
McGinity, J.W., see Walkow, J.C. (35) 91
McGreevy, K.G., see Johnson, D.M. (31) 125
MacGregor, T.R. and Reuning, R.H.
The mouse tail-flick method for evaluation of narcotic antagonist sustained release (38) 171
McHalsky, M., see Kipp, J.E. (34) 1
Macheras, P. and Reppas, C.
Dissolution and in vitro permeation behaviours of dicumarol nitrofurantoin and sulfamethizole in the presence of protein (37) 103
Macheras, P., Koupparis, M. and Apostolelli, E.
Dissolution of 4 controlled-release theophylline formulations in milk (36) 73
Macheras, P., Koupparis, M. and Tsaprounis, C.
Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique (33) 125
Macheras, P., see Poulou, M. (34) 29
Macheras, P., see Rosen, A. (32) 171
McMahon, J., see Rowe, R.C. (31) 281
McMullen, J.N., see Bechard, S. (31) 91
McMullen, J.N., see Bechard, S. (32) 71
Magarotto, L., see Carli, F. (33) 115
Magill, A., see Powell, M.F. (35) 61
Magnard, F., see Armand, J.Y. (40) 33
Magron, P., Rollet, M., Taverdet, J.L. and Vergnaud, J.M.
Spherical oral polymer–drug device with two polymers for constant drug delivery (38) 91
Mahrous, G.M., see Gouda, M.W. (37) 277
Maibach, H.I., see Gummer, C.L. (40) 101
Mailloux, A.T., see Mitra, A.K. (32) 133
Maincen, P., see Henry-Michelland, S. (35) 121
Malakh, A., see Najib, N.M. (32) 229
Maltby, S., see Murphy, A. (38) 257
Marom, G., see Benita, S. (33) 71
Marques, M.L., see Asuero, A.G. (40) 43
Marriott, C., see Kearney, P. (35) 211
Marriott, C., see Kearney, P. (38) 211
Marszall, L.
Effect of choline derivatives on the cloud point of mixed ionic–non-ionic surfactants (39) 263
Martin, R.J., Denyer, S.P. and Hadgraft, J.
Skin metabolism of topically applied compounds (39) 23
Martín-Villodre, A., see Plá-Delfina, J.M. (37) 49
Martinez-Pacheco, R., Vila-Jato, J.L., Souto, C. and Ramos, T.
Controlled release of cephalexin from double-layer tablets containing small proportions of acrylic resins (32) 99
Mason, W.D., Conklin, J.D. and Hailey, F.J.
Relative bioavailability of four macrocrystalline nitrofurantoin capsules (36) 105
Mason, W.D., see Melethil, S. (31) 83
Matsukawa, Y., see Sasaki, H. (36) 147
Matsumoto, S., see Takakura, Y. (37) 135
Mayer, J.M., see Repond, C. (38) 47
Meijer, D.K.F., see Moolenaar, F. (33) 249
Melethil, S., Mason, W.D. and Chang, C.-J.
Dose-dependent absorption and excretion of vitamin C in humans (31) 83
Menzies, A.R. and Edwards, H.E.
Some of the biological properties of factor X-fractionated heparin (37) 65
Merkus, F.W.H.M., see Duchateau, G.S.M.J.E. (31) 193
Merkus, F.W.H.M., see Duchateau, G.S.M.J.E. (31) 275
Merkus, F.W.H.M., see Duchateau, G.S.M.J.E. (34) 131
Meunier, M.S.H., see Desager, J.-P. (31) 179
Michniak-Mikolajczak, B.B., Barry, B.W. and Waller, I.L.
A microbalance technique for measuring water vapour uptake and release by stratum corneum in vitro (31) 247
Middleton, D.L., see Ghebre-Sellassie, I. (31) 43
Mikkelson, T.J., see Mitra, A.K. (37) 19
Mikkelson, T.J., see Mosher, G.L. (39) 113
Minkov, E., see Bogdanova, S. (38) 99
Mitchell, A.G., see Suryanarayanan, R. (32) 213
Mitra, A.K. and Mailloux, A.T.
Mitomycin C pharmacokinetics in rats — effect of dose size (32) 133
Mitra, A.K. and Mikkelson, T.J.
Ophthalmic solution buffer systems. II. Effects of buffer type and concentration on the ocular absorption of pilocarpine and a method of ocular bioavailability prediction from physicochemical data (37) 19
Mitra, A.K. and Narurkar, M.M.
Kinetics of azathioprine degradation in aqueous solution (35) 165
Mitra, A.K., see Fort, J.J. (36) 7
Miyake, Y., see Ando, H. (34) 153
Moës, A.J., see Ingani, H.M. (35) 157
Mohamed, A.A., see Kassem, M.A. (32) 47
Møllgaard, B., see Johansen, M. (32) 199
Momin, P., see Devleeschouwer, M.J. (32) 55
Moolenaar, F., Kaufmann, B.G., Visser, J. and Meijer, D.K.F.
Rectal absorption of methadone from dissolution-promoting vehicles (33) 249
Moore, J.A., Pletcher, S.A. and Ross, M.J.
Absorption enhancement of growth hormone from the gastrointestinal tract of rats (34) 35

Morefield, E.M., Feldkamp, J.R., Peck, G.E., White, J.L. and Hem, S.L.
Preformulation information for suspensions (34) 263
Morimoto, K., see Kokubo, H. (35) 181
Morimoto, Y., Sugibayashi, K., Hosoya, K.-i. and Higuchi, W.I.
Penetration enhancing effect of Azone on the transport of 5-fluorouracil across the hairless rat skin (32) 31
Morisaka, K., see Kokubo, H. (35) 181
Morton, D.J., see Ismail, S. (37) 11
Mosher, G.L., Bundgaard, H., Falch, E., Larsen, C. and Mikkelson, T.J.
Ocular bioavailability of pilocarpic acid mono- and diester prodrugs as assessed by miotic activity in the rabbit (39) 113
Motta, A., see Carli, F. (33) 115
Moustafa, M.A., Al-Shora, H.I., Gaber, M. and Gouda, M.W.
Decreased bioavailability of quinidine sulphate due to interactions with adsorbent antacids and antidiarrhoeal mixtures (34) 207
Moustafa, M.A., Babhair, S.A. and Kouta, H.I.
Decreased bioavailability of some antipsychotic phenothiazines due to interactions with adsorbent antacid and antidiarrhoeal mixtures (36) 187
Müller, U., see Waser, P.G. (39) 213
Munz, K., see Waser, P.G. (39) 213
Murakami, M., Takada, K. and Muranishi, S.
Promoting effect of Azone on intestinal absorption of poorly absorbable drugs in rats (31) 231
Murakami, M., see Fukui, H. (31) 239
Murakami, T., see Kadir, S. (33) 235
Murakami, T., see Kadir, S. (40) 257
Muranishi, S., see Fukui, H. (31) 239
Muranishi, S., see Murakami, M. (31) 231
Murphy, A., Maltby, S. and Launchbury, A.P.
Dissolution time, on reconstitution, of a new parenteral formulation of doxorubicin (Doxorubicin Rapid Dissolution) (38) 257
Murray, G.R., see Wilson, C.G. (40) 119
Muscettola, M., see Bocci, V. (32) 103
Myers, M.J., see Aungst, B.J. (38) 199

Nagappa, A.N., see Srivastava, R.C. (38) 239
Nagappa, A.N., see Tandon, A. (32) 39
Najib, N.M., Suleiman, M. and Malakh, A.
Characteristics of the in vitro release of ibuprofen from polyvinylpyrrolidone solid dispersions (32) 229
Najib, N.M., see El-Hinnawi, M.A. (37) 175
Nakai, Y., see El-Gendy, G.A. (31) 25
Naldini, A., see Bocci, V. (32) 103
Naldini, A., see Bocci, V. (34) 111
Nam-Tran, H., see Huu-Phuoc, N. (34) 217
Nannipieri, E., see Carelli, V. (35) 21
Narayana Reddy, M., see Sastry, C.S.P. (39) 137
Narurkar, M.M., see Mitra, A.K. (35) 165
Navarro, A.S., Castaño, A., Lanao, J.M. and Hurlé, A.D.-G.
In vitro interaction between HAPA-gentamicin B and penicillins (37) 113
Navas, M.J., see Asuero, A.G. (34) 81
Navas, M.J., see Asuero, A.G. (40) 43
Nesbitt, R.U., see Ghebre-Sellassie, I. (31) 43
Nesbitt, R.U., see Ghebre-Sellassie, I. (37) 211
Newman, S.P., Pellow, P.G.D. and Clarke, S.W.
Efficient nebulisation of powdered antibiotics (36) 55
Newton, J.M., see Buckton, G. (38) 1
Newton, J.M., see Harrison, P.J. (35) 235
Nicholls, P.J., see Gumbleton, M. (38) 261
Nicklasson, M., Graffner, C. and Nilsson, M.-I.
Assessment of in vivo drug dissolution by means of numerical deconvolution considering gastrointestinal availability (40) 165
Nicklasson, M., Wennergren, B., Lindberg, J., Persson, C., Ahlgren, R., Palm, B., Pettersson, A. and Wenngren, L.
A collaborative in vitro dissolution study using the flow-through method (37) 195
Nicklasson, M., see Fyhr, P. (40) 193
Nicolay, K., see Talsma, H. (37) 171
Nielsen, N.M. and Bundgaard, H.
Prodrugs as drug delivery systems. 68. Chemical and plasma-catalyzed hydrolysis of various esters of benzoic acid: a reference system for designing prodrug esters of carboxylic acid agents (39) 75
Nilsson, M.-I., see Nicklasson, M. (40) 165
Nimmerfall, F. and Rosenthaler, J.
Modified release of drug: a way to its quantification (32) 1
Ning, A., see Palin, K.J. (33) 99
Niphadkar, P., see D'Souza, M. (31) 165
Nishihata, T.
Simple formulation of sustained-release tablets of sodium diclofenac and examination in humans (40) 125
Nishihata, T., Kim, S., Liversidge, G.G. and Higuchi, T.
Rectal absorption and lymphatic uptake of Ara-C in rats (31) 185
Nishihata, T., Okamura, Y., Inagaki, H., Sudho, M., Kamada, A., Yagi, T., Kawamori, R. and Shichiri, M.
Trials of rectal insulin suppositories in healthy humans (34) 157
Nishihata, T., Sudho, M., Kamada, A., Keigami, M., Fujimoto, T., Kamide, S. and Tatsumi, N.
Investigation of sustained-release suppository of sodium diclofenac in humans (33) 181
Nishihata, T., Sudoh, M., Inagaki, H., Kamada, A., Yagi, T., Kawamori, R. and Shichiri, M.
An effective formulation for an insulin suppository; examination in normal dogs (38) 83
Nitta, C., see Kadir, S. (40) 257
Nobile, L., Cavrini, V., Raggi, M.A. and Di Pietra, A.M.
Analysis of thiamphenicol glycinate salts in pharmaceutical formulations by derivative UV spectroscopy (40) 85
Noguchi, T., see Charman, W.N.A. (33) 155
Noguchi, T., see Charman, W.N.A. (33) 173

Ohwaki, T., see Ando, H. (34) 153
Okamura, Y., see Nishihata, T. (34) 157
Okhamafe, A.O. and York, P.
Interaction phenomena in pharmaceutical film coatings and testing methods (39) 1

O'Reilly, S., Wilson, C.G. and Hardy, J.G.
The influence of food on the gastric emptying of multiparticulate dosage forms (34) 213
Othman, S., see Shaheen, O. (38) 123
Otten, M., see Boussard, P. (32) 91
Ozil, P., see Rochat, M.H. (38) 79

Padmalatha Devi, K., see Baveja, S.K. (39) 39
Pai, S.H., see Law, S.L. (32) 237
Palin, K.J., Philips, A.J. and Ning, A.
The oral absorption of cefoxitin from oil and emulsion vehicles in rats (33) 99
Palin, K.J., see Davis, S.S. (32) 85
Palin, K.J., see Reid, A.S. (40) 181
Palin, K.J., see Young, C. (40) 187
Palm, B., see Nicklasson, M. (37) 195
Papisov, M.I. and Torchilin, V.P.
Magnetic drug targeting. II. Targeted drug transport by magnetic microparticles: factors influencing therapeutic effect (40) 207
Papisov, M.I., Savelyev, V.Y., Sergienko, V.B. and Torchilin, V.P.
Magnetic drug targeting. I. In vivo kinetics of radiolabelled magnetic drug carriers (40) 201
Parker, M.S., see Fassihi, A.R. (31) 271
Paronen, T.P., see Vidgrén, M.T. (35) 139
Paronen, T.P., see Vidgren, M.T. (37) 239
Paronen, T.P., see Vidgren, M.T. (39) 101
Paronen, T.P., see Vidgren, M.T. (39) 107
Parr, A., Beihn, R.M. and Jay, M.
Radiolabeling of an enteric coated tablet by (n,γ) radioactivation of erbium-170 for scintigraphic imaging (32) 251
Parr, A., see Sangekar, S. (35) 187
Parr, G.D., see Farraj, N.F. (38) 39
Parr, G.D., see Jones, S.P. (33) 105
Parr, G.D., see Jones, S.P. (36) 223
Passmore, P., see McElnay, J.C. (33) 195
Patel, C.I., Staniforth, J.N. and Lindley, M.
Fatigue failure behaviour of direct compression excipients (39) 93
Patriarche, G.J., see Vincké, B.J. (32) 61
Patton, T.F., see Ahmed, I. (34) 163
Patton, T.F., see Ahmed, I. (38) 9
Payton, R., Rabinow, B. and Raghavan, N.
Application of radiotracer method for precise determination of water vapor transmission characteristics of unit dose packaging systems (33) 257
Peach, J., see Wilson, C.G. (40) 119
Pearson, A., Shankland, N. and Salole, E.G.
The molecular weight of liquid paraffin by cryoscopy (34) 185
Peck, G.E., see Morefield, E.M. (34) 263
Pellow, P.G.D., see Newman, S.P. (36) 55
Peppas, N.A., see Ponchel, G. (38) 65
Perfetto, L., see Zingerman, J.R. (36) 141
Peris-Ribera, J.E., see Plá-Delfina, J.M. (37) 49
Perrier, D.G., see Gupta, P.K. (33) 137
Perrier, D.G., see Gupta, P.K. (33) 147
Persicaner, P.H.R., see Fassihi, A.R. (37) 167
Persson, C., see Nicklasson, M. (37) 195
Pettersson, A., see Nicklasson, M. (37) 195
Pfluger, B., see Waser, P.G. (39) 213
Philips, A.J., see Palin, K.J. (33) 99
Pico, A.R., see De Bolós, J. (40) 175
Pieters, F.A.J.M. and Zuidema, J.
Some comments on a method to quantify modified drug release (39) 267
Piippo, I., see Laine, E. (38) 33
Pikal, M.J. and Grant, D.J.W.
A theoretical treatment of changes in energy and entropy of solids caused by additives or impurities in solid solution (39) 243
Pilpel, N., see Itiola, O.A. (31) 99
Plá-Delfina, J.M., Buendía, M.D.P., Casabó, V.G., Peris-Ribera, J.E., Sánchez-Moyano, E. and Martín-Villodre, A.
Absorption–partition relationships for true homologous series of xenobiotics as a possible approach to study mechanisms of surfactants in absorption. I. Aromatic amines in rat colon (37) 49
Plane, J.H., see Allwood, M.C. (31) 1
Pletcher, S.A., see Moore, J.A. (34) 35
Ponchel, G., Touchard, F., Wouessidjewe, D., Duchêne, D. and Peppas, N.A.
Bioadhesive analysis of controlled-release systems. III. Bioadhesive and release behavior of metronidazole-containing poly(acrylic acid)-hydroxypropyl methylcellulose systems (38) 65
Pongpaibul, Y. and Whitworth, C.W.
Preparation and in vitro dissolution characteristics of propranolol microcapsules (33) 243
Pontikos, N.M., see Acree, Jr., W.E. (31) 225
Pope, D.G., see Zingerman, J.R. (36) 141
Potman, R.P., see Beijnen, J.H. (34) 247
Poulou, M. and Macheras, P.
Determination of nitrofurantoin in urine by derivative spectroscopy (34) 29
Powell, M.F., Magill, A. and Becker, A.R.
Non-steroidal anti-psoriatic prodrugs. Hydrolysis and aminolysis of naphthyl esters in aqueous solution (35) 61
Prakongpan, S., see Swarbrick, J. (32) 21
Pretzer, D. and Repta, A.J.
Stability of the experimental anticancer agent [[(4-methoxyphenyl)sulfonyl]hydrazono]acetic acid (NSC-267213). I. Kinetics and mechanism of degradation (38) 147
Pretzer, D. and Repta, A.J.
Stability of the experimental anticancer agent [[(4-methoxyphenyl)sulfonyl]hydrazono]acetic acid (NSC-267213). II. Effect of structural modification on stability and mechanism of degradation (38) 161
Pritchard, R.A., see Johnson, D.M. (31) 125
Pugh, W.J., see Russell, A.D. (35) 227
Puisieux, F., see Roblot-Treupel, L. (31) 131

Quarton, M., see Lenaerts, V. (39) 121

Quigley, J.M., see Irwin, V.P. (34) 241
Quincey, S.M., see Staniforth, J.N. (32) 177

Rabinow, B., see Payton, R. (33) 257
Raby, C., see Jambut-Absil, A.C. (35) 129
Raggi, M.A., see Di Pietra, A.M. (35) 13
Raggi, M.A., see Nobile, L. (40) 85
Raghavan, N., see Jacobs, G.P. (32) 151
Raghavan, N., see Payton, R. (33) 257
Rainova, L., see Bogdanova, S. (38) 99
Rajala, R., see Laine, E. (38) 33
Rajendraprasad Singh, N., see Sastry, C.S.P. (39) 137
Rakić, R., Jovanović, M. and Djurić, Z.
Relation between viscosity of carboxymethylcellulose aqueous solutions and charge of its particles in the presence of preservatives (39) 47
Ramos, T., see Martinez-Pacheco, R. (32) 99
Rao, K.P., see Jeyanthi, R. (35) 177
Rao, K.V.R., see Baveja, S.K. (31) 169
Rao, K.V.R., see Baveja, S.K. (39) 39
Raz, I., see Hussein, Z. (37) 97
Recamales, A.F., see Asuero, A.G. (34) 81
Reid, A.S., Thomas, N.W., Palin, K.J. and Gould, P.L.
Formation of Fenbufin suppositories. I. Quantitative histological assessment of the rectal mucosa of rats following treatment with suppository bases (40) 181
Reid, A.S., see Young, C. (40) 187
Renema, J., see Beijnen, J.H. (34) 247
Renoux, R., see Aiache, J.-M. (39) 235
Repond, C., Mayer, J.M., Van de Waterbeemd, H., Testa, B. and Linert, W.
Thermodynamics and mechanism of partitioning of pyridylalkanamides in *n*-octanol/water and di-*n*-butyl ether/water (38) 47
Reppas, C., see Macheras, P. (37) 103
Repta, A.J., see Gogate, U.S. (40) 235
Repta, A.J., see Gogate, U.S. (40) 249
Repta, A.J., see Pretzer, D. (38) 147
Repta, A.J., see Pretzer, D. (38) 161
Reuning, R.H., see MacGregor, T.R. (38) 171
Reynolds, J.R., see Hardy, J.G. (31) 151
Ridout, G., see Hadgraft, J. (39) 149
Rieg-Falson, F., see Lenaerts, V. (39) 121
Riley, C.M., see Stout, S.A. (37) 257
Rim, S., Audus, K.L. and Borchardt, R.T.
Relationship of octanol/buffer and octanol/water partition coefficients to transcellular diffusion across brain microvessel endothelial cell monolayers (32) 79
Roberts, R.J. and Rowe, R.C.
Brittle/ductile behaviour in pharmaceutical materials used in tabletting (36) 205
Roberts, R.J. and Rowe, R.C.
The Young's modulus of pharmaceutical materials (37) 15
Roblot-Treupel, L. and Puisieux, F.
Distribution of magnesium stearate on the surface of lubricated particles (31) 131
Rochat, M.H., Ozil, P., Antonelli, I. and Verain, A.
Modelling of dynamic behaviour for total parenteral nutrition (38) 79
Rogers, J.A., see Betageri, G.V. (36) 165
Rogers, N.J., see Aungst, B.J. (33) 225
Rohera, B.D., see Leuenberger, H. (38) 109
Rolland, A., Bourel, D., Genetet, B. and Le Verge, R.
Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes (39) 173
Rollet, J., see Armand, J.Y. (40) 33
Rollet, M., see Farah, N. (36) 81
Rollet, M., see Magron, P. (38) 91
Rosen, A., Macheras, P. and Howe, K.D.
The use of constant volume ultrafiltration for dissolution studies (32) 171
Rosenthaler, J., see Nimmerfall, F. (32) 1
Rosing, H., see Beijnen, J.H. (32) 111
Ross, M.J., see Moore, J.A. (34) 35
Rossing, N., see Illum, L. (39) 189
Rowe, R.C. and Sadeghnejad, G.R.
The rheology of microcrystalline cellulose powder/water mixes – measurement using a mixer torque rheometer (38) 227
Rowe, R.C., McMahon, J. and Stewart, R.F.
The stability of oil-in-water emulsions containing cetrimide and cetostearyl alchohol (31) 281
Rowe, R.C., see Harrison, P.J. (35) 235
Rowe, R.C., see Roberts, R.J. (36) 205
Rowe, R.C., see Roberts, R.J. (37) 15
Rowe, R.C., see Sakellariou, P. (31) 175
Rowe, R.C., see Sakellariou, P. (31) 55
Rowe, R.C., see Sakellariou, P. (34) 93
Rubessa, F., see Lovrecich, M. (40) 63
Rubinstein, M.H. and Jackson, I.M.
Stress relaxation behaviour of compacts of sodium chloride and polyethylene (36) 99
Rubinstein, M.H., see Ford, J.L. (40) 223
Rubinstein, M.H., see Waring, M.J. (36) 29
Rubinstein, M.H., see Waring, M.J. (40) 15
Rue, P.J., see Cutt, T. (33) 81
Rue, P.J., see Cutt, T. (39) 157
Russell, A.D. and Furr, J.R.
Comparative sensitivity of smooth, rough and deep rough strains of *Escherichia coli* to chlorhexidine, quaternary ammonium compounds and dibromopropamidine isethionate (36) 191
Russell, A.D. and Furr, J.R.
The effects of antiseptics, disinfectants and preservatives on smooth, rough and deep rough strains of *Salmonella typhimurium* (34) 115
Russell, A.D., Furr, J.R. and Pugh, W.J.
Sequential loss of outer membrane lipopolysaccharide and sensitivity of *Escherichia coli* to antibacterial agents (35) 227
Russell, A.D., see Shaker, L.A. (34) 51

Saarnivaara, K., see Laine, E. (38) 33
Sadeghnejad, G.R., see Rowe, R.C. (38) 227
Saettone, M.F., Giannaccini, B., Guiducci, A. and Savigni, P.
Semisolid ophthalmic vehicles. III. An evaluation of four organic hydrogels containing pilocarpine (31) 261
Sågström, A., see Alderborn, G. (37) 155
Sakane, T., see Yamamoto, A. (39) 255
Sakellariou, P., Rowe, R.C. and White, E.F.T.
An evaluation of the interaction and plasticizing efficiency of the polyethylene glycols in ethyl cellulose and hydroxypropyl methylcellulose films using the torsional braid pendulum (31) 55
Sakellariou, P., Rowe, R.C. and White, E.F.T.
Polymer/polymer interaction in blends of ethyl cellulose with both cellulose derivatives and polyethylene glycol 6000 (34) 93
Sakellariou, P., Rowe, R.C. and White, E.F.T.
The solubility parameters of some cellulose derivatives and polyethylene glycols used in tablet film coating (31) 175
Salemink, P.J.M., see Fransen, G.J. (33) 27
Salole, E.G., see Al-Dujaili, H. (34) 67
Salole, E.G., see Al-Dujaili, H. (34) 75
Salole, E.G., see Pearson, A. (34) 185
Samaha, M.W., see Gadalla, M.A.F. (38) 71
Sánchez-Moyano, E., see Plá-Delfina, J.M. (37) 49
Sangekar, S., Vadino, W.A., Chaudry, I., Parr, A., Beihn, R. and Digenis, G.
Evaluation of the effect of food and specific gravity of tablets on gastric retention time (35) 187
Sankar, D.G., see Sastry, C.S.P. (39) 137
Sasaki, H., Matsukawa, Y., Hashida, M. and Sezaki, H.
Characterization of alkylcarbamoyl derivatives of 5-fluorouracil and their application to liposome (36) 147
Sastry, C.S.P., Rajendraprasad Singh, N., Narayana Reddy, M. and Sankar, D.G.
Spectrophotometric determination of menadione and menadione sodium bisulfite in pharmaceutical preparations (39) 137
Sauzières, J., see Henry-Michelland, S. (35) 121
Savelyev, V.Y., see Papisov, M.I. (40) 201
Savigni, P., see Saettone, M.F. (31) 261
Schneider, J.A., see Benjamin, E.J. (35) 73
Schreier, H., Abra, R.M., Kaplan, J.E. and Hunt, C.A.
Murine plasma fibronectin depletion after intravenous injection of liposomes (37) 233
Sekine, Y., see Yamaguchi, T. (37) 127
Sekulović, D. and Birmančević, M.
Investigation of the properties of phenacetin tablets: dependence on the concentration of binding and disintegration agents (32) 269
Sekulović, D. and Zajić, L.
Investigation of the properties of Compactrol tablets relative to the type of disintegrant used (38) 255
Sergienko, V.B., see Papisov, M.I. (40) 201
Sezaki, H., see Higaki, K. (36) 131
Sezaki, H., see Sasaki, H. (36) 147
Sezaki, H., see Takakura, Y. (37) 135
Sezaki, H., see Takakura, Y. (37) 145
Sezaki, H., see Yamamoto, A. (39) 255
Shah, V.P., Tymes, N.W., Yamamoto, L.A. and Skelly, J.P.
In vitro dissolution profile of transdermal nitroglycerin patches using paddle method (32) 243
Shaheen, O., Othman, S., Jalal, I., Awidi, A. and Al-Turk, W.
Comparison of pharmacokinetics and pharmacodynamics of a conventional and a new rapidly dissolving glibenclamide preparation (38) 123
Shaker, L.A., Russell, A.D. and Furr, J.R.
Aspects of the action of chlorhexidine on bacterial spores (34) 51
Shami, E.G., see Aungst, B.J. (38) 199
Shankar, M., see Srivastava, R.C. (38) 239
Shankland, N., see Pearson, A. (34) 185
Shefter, E., see Aungst, B.J. (33) 225
Shefter, E., see Aungst, B.J. (38) 199
Shefter, E., see Hussain, M.A. (36) 127
Shichiri, M., see Nishihata, T. (34) 157
Shichiri, M., see Nishihata, T. (38) 83
Sidahmed, A.M., see McElnay, J.C. (31) 107
Silver, K.G., see Waranis, R.P. (36) 211
Sjöholm, I., see Artursson, P. (32) 165
Sjöholm, I., see Stjärnkvist, P. (40) 215
Skelly, J.P., see Shah, V.P. (32) 243
Sloan, K.B., see Koch, S.A.M. (35) 243
Sloan, K.B., see Waranis, R.P. (36) 211
Smedsrød, B., see Laakso, T. (36) 253
Smets, P., see Heyman, M. (37) 33
Smith, B.V., see Beezer, A.E. (38) 251
Smith, W.M., see Ackermann, C. (36) 67
Snider, B.G., see Hill, R.A. (36) 175
Souto, C., see Martinez-Pacheco, R. (32) 99
Speiser, P., see Harmia, T. (33) 187
Speiser, P., see Harmia, T. (33) 45
Speiser, P.P., see Gipps, E.M. (40) 23
Spies, F., see Jousma, H. (35) 263
Spring, M.S., see Cutt, T. (33) 81
Spring, M.S., see Cutt, T. (39) 157
Srivastava, R.C., Shankar, M., Tandon, A. and Nagappa, A.N.
Liquid membrane phenomena in anticancer drugs. Studies on 5-fluorouracil and its derivatives (38) 239
Srivastava, R.C., see Tandon, A. (32) 39
Staniforth, J.N. and Iveson, S.R.
An investigation of the use of UV fluorescence microscopy as a method for quantifying the homogeneity of powder mixes (31) 145
Staniforth, J.N. and Quincey, S.M.
Granulation monitoring in a planetary mixer using a probe vibration analysis technique (32) 177
Staniforth, J.N., Baichwal, A.R. and Hart, J.P.
Interpretation of creep behaviour of microcrystalline cellulose powders and granules during compaction (40) 267
Staniforth, J.N., Walker, S. and Flanders, P.
Granulation monitoring in a high speed mixer/processor using a probe vibration analysis technique (31) 277
Staniforth, J.N., see Patel, C.I. (39) 93

Steerenberg, P.A., Storm, G., De Groot, G., Bergers, J.J., Claessen, A. and De Jong, W.H.
Liposomes as a drug carrier system for *cis*-diammine-dichloroplatinum(II). I. Binding capacity, stability and tumor cell growth inhibition in vitro (40) 51
Stella, V.J., see Charman, W.N.A. (33) 155
Stella, V.J., see Charman, W.N.A. (33) 165
Stella, V.J., see Charman, W.N.A. (33) 173
Stella, V.J., see Charman, W.N.A. (34) 175
Stewart, P.J., see Kulvanich, P. (35) 111
Stewart, P.J., see Kulvanich, P. (36) 243
Stewart, P.J., see Kulvanich, P. (39) 51
Stewart, R.F., see Rowe, R.C. (31) 281
Stjärnkvist, P., Artursson, P., Brunmark, A., Laakso, T. and Sjöholm, I.
Biodegradable microspheres. VIII. Killing of *Leishmania donovani* in cultured macrophages by microparticle-bound primaquine (40) 215
Storm, G., see Steerenberg, P.A. (40) 51
Stout, S.A. and Riley, C.M.
Hydrolysis of L-phenylalanine mustard (melphalan). II. Further observations on the effects of pH, chloride ions and buffers on the rate of reaction (37) 257
Sudho, M., see Nishihata, T. (33) 181
Sudho, M., see Nishihata, T. (34) 157
Sudoh, M., see Nishihata, T. (38) 83
Sugibayashi, K., see Morimoto, Y. (32) 31
Suleiman, M., see Najib, N.M. (32) 229
Summers, M.P., see Hilton, J.E. (31) 157
Summers, M.P., see Hilton, J.E. (32) 13
Summers, M.P., see Hilton, J.E. (33) 219
Suryanarayanan, R. and Mitchell, A.G.
Phase transitions of calcium gluceptate (32) 213
Suzuki, K., see Swarbrick, J. (32) 21
Svensson, C.K.
Effect of single and short-term multiple exposure to honeybee venom on the disposition of antipyrine in the rat (37) 163
Swarbrick, J., Prakongpan, S. and Suzuki, K.
Sustained release delivery systems. III. Preparation and in vitro dissolution of surface-reacted dapsone particles (32) 21

Taggart, A.J., see McElnay, J.C. (33) 195
Takada, K., see Fukui, H. (31) 239
Takada, K., see Murakami, M. (31) 231
Takakura, Y., Kitajima, M., Matsumoto, S., Hashida, M. and Sezaki, H.
Development of a novel polymeric prodrug of mitomycin C, mitomycin C–dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities (37) 135
Takakura, Y., Atsumi, R., Hashida, M. and Sezaki, H.
Development of a novel polymeric prodrug of mitomycin C, mitomycin C–dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration (37) 145
Takla, P.G., see Gassim, A.E.H. (34) 23
Talsma, H., Jousma, H., Nicolay, K. and Crommelin, D.J.A.
Multilamellar or multivesicular vesicles? (37) 171
Talsma, H., see Jousma, H. (35) 263
Tandon, A., Nagappa, A.N. and Srivastava, R.C.
Liquid membrane phenomenon in vitamin E: studies on α-tocopherol (32) 39
Tandon, A., see Srivastava, R.C. (38) 239
Tatsumi, N., see Nishihata, T. (33) 181
Taverdet, J.L., see Armand, J.Y. (40) 33
Taverdet, J.L., see Eddine, A. (32) 143
Taverdet, J.L., see Farah, N. (36) 81
Taverdet, J.L., see Magron, P. (38) 91
Tavipatana, W. and Ayres, J.W.
Proxyphylline and theophylline pharmacokinetics when administered concomitantly in rabbits (38) 139
Tawashi, R., see Akbarieh, M. (35) 81
Taylor, G., see Gumbleton, M. (38) 261
Taylor, P.J., see De Meere, A.L.J. (31) 209
Taylor, W.F., see Johnson, D.M. (31) 125
Teh, G.W., see Law, S.L. (32) 237
Terada, K., see El-Gendy, G.A. (31) 25
Testa, B., see Repond, C. (38) 47
Thomas, N.W., see Reid, A.S. (40) 181
Thomas, N.W., see Young, C. (40) 187
Thompson, S.P., see White, D.A. (40) 151
Tiedt, L.R., see Du Plessis, J. (34) 173
Tighe, B.J., see Gould, P.L. (38) 231
Timmermans, J., see Ingani, H.M. (35) 157
Timoney, R.F., see Irwin, V.P. (34) 241
Tomlinson, E., see Burgess, D.J. (39) 129
Tomlinson, E., see De Meere, A.L.J. (31) 209
Tønnesen, H.H. and Karlsen, J.
Studies on curcumin and curcuminoids. X. The use of curcumin as a formulation aid to protect light-sensitive drugs in soft gelatin capsules (38) 247
Tønnesen, H.H., see Hardy, J.G. (37) 245
Torchilin, V.P., see Papisov, M.I. (40) 201
Torchilin, V.P., see Papisov, M.I. (40) 207
Torricelli, C., see Carli, F. (33) 115
Touchard, F., see Ponchel, G. (38) 65
Touitou, E.
Transdermal delivery of anxiolytics: in vitro skin permeation of midazolam maleate and diazepam (33) 37
Triqueneaux, C., see Lenaerts, V. (39) 121
Tsaprounis, C., see Macheras, P. (33) 125
Tucker, I.G., see Koh, G.-L. (34) 183
Tymes, N.W., see Shah, V.P. (32) 243

Uekama, K., see Hirayama, F. (35) 193
Uekama, K., see Hoshino, T. (38) 265
Uekama, K., see Kikuchi, M. (38) 191
Underberg, W.J.M., see Beijnen, J.H. (31) 75
Underberg, W.J.M., see Beijnen, J.H. (32) 111
Underberg, W.J.M., see Beijnen, J.H. (32) 123
Underberg, W.J.M., see Beijnen, J.H. (34) 247
Utsumi, E., see Yamamoto, A. (39) 255

Vachon, M.G. and Grant, D.J.W.
Enthalpy–entropy compensation in pharmaceutical solids (40) 1
Vadas, E.B., see Cotton, M.L. (40) 129
Vadino, W.A., see Sangekar, S. (35) 187
Van Bennekom, W.P., see Leeuwenkamp, O.R. (33) 1
Van de Biggelaar, H., see Vromans, H. (35) 29
Van de Griend, J., see Van Henegouwen, G.M.J.B. (35) 259
Van der Houwen, O.A.G.J., see Beijnen, J.H. (31) 75
Van der Houwen, O.A.G.J., see Beijnen, J.H. (32) 123
Van der Mark, E.J., see Leeuwenkamp, O.R. (33) 1
Van der Watt, J.G.
The effect of the particle size of microcrystalline cellulose on tablet properties in mixtures with magnesium stearate (36) 51
Van de Waterbeemd, H., see Repond, C. (38) 47
Van de Zijde, H.J., see Van Henegouwen, G.M.J.B. (35) 259
Van Henegouwen, G.M.J.B., Van de Zijde, H.J., Van de Griend, J. and De Vries, H.
Photochemical decomposition of diphenhydramine in water (35) 259
Van Henegouwen, G.M.J.B., see Busker, R.W. (36) 113
Van Ooijen, R.D., see Beijnen, J.H. (34) 247
Van Rooij, H.H., see Grünbauer, H.J.M. (32) 187
Van Wyk, C.J., see Du Plessis, J. (34) 173
Venkataramanan, R., see D'Souza, M. (31) 165
Verain, A., see Rochat, M.H. (38) 79
Vergnaud, J.M., see Armand, J.Y. (40) 33
Vergnaud, J.M., see Eddine, A. (32) 143
Vergnaud, J.M., see Farah, N. (36) 81
Vergnaud, J.M., see Magron, P. (38) 91
Vidgrén, M.T., Vidgrén, P.A. and Paronen, T.P.
Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate (35) 139
Vidgren, M.T., Kärkkäinen, A., Karjalainen, P. and Paronen, T.P.
A novel labelling method for measuring the deposition of drug particles in the respiratory tract (37) 239
Vidgren, M.T., Kärkkäinen, A., Paronen, T.P. and Karjalainen, P.
Respiratory tract deposition of ^{99m}Tc-labelled drug particles administered via a dry powder inhaler (39) 101
Vidgren, M.T., Paronen, T.P., Kärkkäinen, A. and Karjalainen, P.
Effect of extension devices on the drug deposition from inhalation aerosols (39) 107
Vidgrén, P.A., see Vidgrén, M.T. (35) 139
Vila-Jato, J.L., see Martinez-Pacheco, R. (32) 99
Vincké, B.J., Devleeschouwer, M.J., Dony, J. and Patriarche, G.J.
Efficiency of bioconversion of steroids by *Fusarium oxysporum* into Δ1,4-androstadiene-3,17-dione using gas chromatography (32) 61
Visser, J., see Moolenaar, F. (33) 249
Voskuilen, M.C.H., see Beijnen, J.H. (31) 75
Voskuilen, M.C.H., see Beijnen, J.H. (34) 247
Vromans, H., Bolhuis, G.K., Lerk, C.F. and Kussendrager, K.D.
Studies on tableting properties of lactose. VIII. The effect of variations in primary particle size, percentage of amorphous lactose and addition of a disintegrant on the disintegration of spray-dried lactose tablets (39) 201
Vromans, H., Bolhuis, G.K., Lerk, C.F. and Kussendrager, K.D.
Studies of tableting properties of lactose. IX. The relationship between particle structure and compactibility of crystalline lactose (39) 207
Vromans, H., Bolhuis, G.K., Lerk, C.F., Van de Biggelaar, H. and Bosch, H.
Studies on tableting properties of lactose. VII. The effect of variations in primary particle size and percentage of amorphous lactose in spray dried lactose products (35) 29

Walker, I.M., see Davis, S.S. (38) 133
Walker, S., see Staniforth, J.N. (31) 277
Walkow, J.C. and McGinity, J.W.
The effect of physicochemical properties on the in vitro diffusion of drug through synthetic membranes and pigskin. I. Methyl salicylate (35) 91
Walkow, J.C. and McGinity, J.W.
The effect of physicochemical properties on the in vitro diffusion of drug through synthetic membranes and pigskin. II. Salicylic acid (35) 103
Waller, I.L., see Michniak-Mikolajczak, B.B. (31) 247
Walters, K.A., see Hadgraft, J. (32) 257
Waranis, R.P., Silver, K.G. and Sloan, K.B.
The solubility parameter of vehicles as a predictor of relative vehicle effects on the diffusion of 6-mercaptopurine (36) 211
Waring, M.J., Rubinstein, M.H. and Howard, J.R.
Acoustic emission of pharmaceutical materials during compression (36) 29
Waring, M.J., Rubinstein, M.H. and Howard, J.R.
Acoustic emission of pharmaceutical materials: the effect of compression speed, ejection, lubrication and tablet weight (40) 15
Waser, P.G., Müller, U., Kreuter, J., Berger, S., Munz, K., Kaiser, E. and Pfluger, B.
Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice (39) 213
Washington, C. and Davis, S.S.
Ageing effects in parenteral fat emulsions: the role of fatty acids (39) 33
Washington, C., see Gilbert, J.C. (40) 93
Washington, C., see Washington, N. (34) 105
Washington, C., see Washington, N. (39) 163
Washington, N., Washington, C. and Wilson, C.G.
Gastric distribution and residence time of two anti-reflux formulations (39) 163
Washington, N., Washington, C., Wilson, C.G. and Davis, S.S.
What is "Liquid Gaviscon"? A comparison of four international formulations (34) 105

Washington, N., see Davis, S.S. (35) 253
Washington, N., see Wilson, C.G. (38) 221
Washington, N., see Wilson, C.G. (40) 119
Watanabe, S., see Ando, H. (34) 153
Watari, N., see Kaneniwa, N. (31) 33
Watari, N., see Kaneniwa, N. (34) 231
Weiner, N., see Chiang, C.-M. (37) 75
Weiner, N., see Chiang, C.-M. (40) 143
Wennergren, B., see Nicklasson, M. (37) 195
Wenngren, L., see Nicklasson, M. (37) 195
Whateley, T.L., see Law, T.K. (33) 65
White, D.A., Thompson, S.P., Wilson, C.G. and Bell, G.D.
A pharmacokinetic comparison of two delayed-release peppermint oil preparations, Colpermin and Mintec, for treatment of the irritable bowel syndrome (40) 151
White, E.F.T., see Sakellariou, P. (31) 175
White, E.F.T., see Sakellariou, P. (31) 55
White, E.F.T., see Sakellariou, P. (34) 93
White, J.L., see Morefield, E.M. (34) 263
Whitworth, C.W., see Pongpaibul, Y. (33) 243
Wilkinson, P.K., see Zingerman, J.R. (36) 141
Wilson, C.G., Washington, N., Hardy, J.G. and Bond, S.W.
The influence of food on the absorption of acyclovir: a pharmacokinetic and scintigraphic assessment (38) 221
Wilson, C.G., Washington, N., Peach, J., Murray, G.R. and Kennerley, J.
The behaviour of a fast-dissolving dosage form (Expidet) followed by γ-scintigraphy (40) 119
Wilson, C.G., see Davis, S.S. (32) 85
Wilson, C.G., see Davis, S.S. (35) 253
Wilson, C.G., see Fitzgerald, P. (40) 81
Wilson, C.G., see O'Reilly, S. (34) 213
Wilson, C.G., see Washington, N. (34) 105
Wilson, C.G., see Washington, N. (39) 163
Wilson, C.G., see White, D.A. (40) 151
Winkens, J.H.M., see Busker, R.W. (36) 113
Withington, R., see Farraj, N.F. (38) 39
Wood, E., see Hardy, J.G. (38) 103
Woolfson, A.D., McCafferty, D.F. and Launchbury, A.P.
Stabilisation of hydrotropic temazepam parenteral formulations by lyophilisation (34) 17
Woolfson, A.D., see McCafferty, D.F. (38) 59
Woolfson, A.D., see McCafferty, D.F. (31) 9
Wotton, P.K., see Hadgraft, J. (32) 257
Wotton, P.K., see Johansen, M. (32) 199
Wouessidjewe, D., see Ponchel, G. (38) 65
Wu, D.W., see Cotton, M.L. (40) 129

Yagi, T., see Nishihata, T. (34) 157
Yagi, T., see Nishihata, T. (38) 83
Yahya, A.M., McElnay, J.C. and D'Arcy, P.F.
Investigation of chloroquine binding to plastic materials (34) 137
Yahya, A.M., McElnay, J.C. and D'Arcy, P.F.
Photodegradation of frusemide during storage in burette administration sets (31) 65
Yamaguchi, T., Ikeda, C. and Sekine, Y.
Intestinal absorption of a β-adrenergic blocking agent nadolol. Enhancement of in situ and in vivo absorption of nadolol in rats (37) 127
Yamamoto, A., Utsumi, E., Sakane, T., Kawaratani, T., Hashida, M. and Sezaki, H.
Enhanced absorption of salicylic acid and sulfanilamide by the synthetic immunomodulator levamisole in rats (39) 255
Yamamoto, K., see El-Gendy, G.A. (31) 25
Yamamoto, L.A., see Shah, V.P. (32) 243
Yashiki, T., see Yoshimura, Y. (38) 179
Yata, N., see Kadir, S. (33) 235
Yata, N., see Kadir, S. (40) 257
York, P., see Doherty, C. (34) 197
York, P., see Okhamafe, A.O. (39) 1
Yoshimura, Y., Hamaguchi, N. and Yashiki, T.
Synthesis and oral absorption of acyloxymethyl esters of 7β-(2-(2-aminothiazol-4-yl)acetamido)-3- (((1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl)thio)- methyl)ceph-3-em-4-carboxylic acid (cefotiam) (38) 179
Young, C., Palin, K.J., Reid, A.S., Thomas, N.W. and Gould, P.L.
Formulation of Fenbufen suppositories. II. Selection of a suppository base using dissolution studies and histological studies in rats (40) 187

Zajić, L., see Sekulović, D. (38) 255
Zaki, I., see Hardy, J.G. (37) 245
Zimmermann, I.
Determination of overlapping pK_a values from solubility data (31) 69
Zingerman, J.R., Pope, D.G., Wilkinson, P.K. and Perfetto, L.
Automatic injector apparatus for studying the injectability of parenteral formulations for animal health (36) 141
Zuidema, J., see Duchateau, G.S.M.J.E. (31) 193
Zuidema, J., see Duchateau, G.S.M.J.E. (31) 275
Zuidema, J., see Duchateau, G.S.M.J.E. (34) 131
Zuidema, J., see Duchateau, G.S.M.J.E. (39) 87
Zuidema, J., see Pieters, F.A.J.M. (39) 267
Zuniga, G., see Johnson, D.M. (31) 125

International Journal of Pharmaceutics, (1988) 19–31
Elsevier

Subject Index

Absolute retard effect, (39) 267
Absorption, (31) 83; (32) 13; (33) 99; (33) 219; (36) 105
Absorption and desorption of antibiotics, (31) 137
Absorption enhancement, (34) 35
Absorption of interferon from skin, (32) 103
Absorption–partition correlation, (37) 49
Absorption promoter, (31) 231; (33) 235
Absorption rate constant, (31) 33; (34) 9
Absorption site, (31) 119
Acacia, (32) 207
Ac-Di-Sol, (38) 255
Acebutolol, (31) 179
Acetaminophen, (33) 125
Acetonitrile–water, (38) 71
Acetotoluide, (36) 223
Acetylated mitosene degradation products, (32) 111
N-Acetyl-L-cysteine, (40) 85
Acetylsalicylic acid, (34) 259; (37) 203
Acidity constant, (34) 81
Acinetobacter glutaminasificans, (34) 225
Acoustic emission, (36) 29; (39) 93; (40) 15
Acrylic polymer, (37) 211
Acrylic resin, (31) 43; (32) 99
Active targeting, (39) 173
Acute toxicity, (38) 99
Acyclovir, (38) 221
Acyloxyalkoxycarbamate, (40) 235
Acyloxymethyl esters of cefotiam, (38) 179
Adhesion distribution, (35) 111
Adhesion profile, (35) 111
Adhesiveness, (34) 75
Adhesivity, (34) 67
Adipic acid, (36) 17
Adjuvant, (31) 185; (33) 89; (33) 253; (34) 157
β-Adrenoceptor blocking drug, (37) 251
Adriamycin, (38) 257
Adsorbent, (34) 207; (36) 157
Adsorption, (32) 237
Aerosol, (36) 55
Albino rabbit, (34) 163; (38) 9
Albumin microsphere, (33) 137; (39) 129
Albumin nanoparticle, (39) 213
Alginate, (34) 105; (39) 163
Algorithm, (31) 69
Aliphatic esters of metronidazole, (32) 199
Alkaline hydrolysis, (39) 75
Alkanol, (36) 67
Alkylcarbamoyl derivative, (36) 147
Alleviation, (38) 265
Alprenolol, (34) 131
Alprenolol hydrochloride, (39) 39
Aluminium, (33) 261
Aluminium hydroxide–magnesium carbonate mixture, (36) 187
Amberset burettes, (31) 65
Amide, (33) 225
Amine prodrug, (40) 235
Amine prodrug, Acyloxyalkoxycarbamate, (40) 249
Aminoglycosides and penicillins, (37) 113
p-Aminohippuric acid, (38) 261
Aminophylline, (33) 55; (40) 223
Amorphous, (35) 29
Amorphous lactose, (39) 201
Amorphous state, (34) 197
Amoxycillin, (31) 137
Ampicillin, (31) 137; (35) 121
Anaesthetic, (38) 261
Analgesic antagonism, (38) 171
Analysis, (38) 39
Δ1,4-Androstadiene-3,17-dione, (32) 61
Animal health, (36) 141
Animal model, (37) 97
Anion exchange resin, (37) 127
Antacid, (34) 105; (34) 189; (34) 207; (36) 187
Antibacterial activity, (34) 241
Antibacterial agent, (35) 227
Antibiotic, (36) 55
Antibiotic elution, (31) 137
Anticancer drug, (38) 239
Antidiarrhoeal, (34) 207
Antidiarrhoeal adsorbent, (36) 187
Antidote to organophosphorus poisoning, (40) 157; (40) 193
Antiepileptic drug, (36) 1
Anti-inflammatory agent, (33) 195
Antimicrobial activity, (34) 45; (35) 121
Antiparasitic drug, (40) 215
Antipsychotic, (36) 187
Antipyrine, (37) 163
Antiseptic, (34) 45; (34) 115
Antithrombotic agent, (37) 65
Antitumor activity, (36) 147; (37) 135
Aortic soluble fraction, (33) 1
Apparatus, (31) 247
Aqueous acidic solution, (40) 157
Aqueous and hydrophilic solvents, (40) 193
Aqueous dispersion, (31) 43; (37) 211
Area deviation, (32) 1

0378-5173/88/$03.50 © 1988 Elsevier Science Publishers B.V. (Biomedical Division)

Area deviation method, (39) 267
Artificial lipid membrane, (39) 149
Artificial lipoidal membrane, (37) 251
Arylsulfonylhydrazone, (38) 147; (38) 161
Ascorbic acid, (31) 83; (36) 233
L-Asparaginase-L-glutaminase, (34) 225
Aspirin, (31) 25
Assay, (34) 183
Asthma aerosol, (37) 239
Asthma therapy, (39) 101
Atropine, (31) 33
Automation, (34) 1
Autoradiography on macro-, micro- and electron microscopic level, (39) 213
Avicel PH-101, (32) 269; (36) 29
Azathioprine, (35) 165
Azone, (31) 231; (31) 239; (32) 31
Azone-permeation enhancement, (33) 37

Bacterial spore, (34) 51
Base, (40) 181
Bendomonas aeruginosa, (32) 91
Benperidol, (34) 23
Benzaldehyde trace, (35) 13
Benzalkonium Chloride, (37) 27
Benzamide, (37) 185
Benzodiazepine, (36) 113
Benzoic acid, (32) 223
Benzoic acid ester, (39) 75
Benzyl alcohol, (35) 13
Betamethasone, (32) 47
Bifunctional acids, (31) 69
Bifunctional bases, (31) 69
Bile salts, (31) 193
Biliary excretion, (31) 119; (36) 131
Binary mixture, (37) 155
Binary mixtures, (31) 201
Binder, (33) 81; (35) 29
Binding capacity, (37) 127; (39) 207; (40) 51
Binding to plastic, (34) 137
Bioadhesion, (38) 65; (39) 189
Bioavailability, (31) 83; (34) 35; (34) 131; (34) 189; (35) 181; (36) 105; (37) 11; (37) 277; (38) 33; (38) 39; (38) 117; (38) 199; (38) 211; (39) 87; (39) 141; (39) 235; (40) 143
Bioavailability in rat, (36) 1
Bioavailability of intradermal interferon, (32) 103
Biodistribution, (34) 145
Bioerodible polyhydroxybutyrate–polyhydroxyvalerate copolymer, (38) 231
Biological fluid, (38) 59
Bi-phasic zero-order, (33) 137
Biphenyl solubilities, (31) 225
Bismuth subnitrate, (34) 207; (36) 187
Bleomycin, (35) 177
β-Blocker, (36) 165; (39) 39
Blood–brain barrier, (32) 79; (35) 47
Blood concentration, (36) 1
Blood levels, (32) 1
Bonding index, (31) 201
Bovine serum albumin, (32) 237; (37) 103
Brain-specific delivery, (35) 47
Brittle/ductile transition, (36) 205
Brittle fracture index, (31) 99
Bromazepam adsorption onto PVP, (37) 167
Bromazepam interaction, (37) 167
Bromerguride, (31) 69
Bromocriptine, (32) 1
BSA microspheres, (33) 147
Buccal absorption, (40) 119
Buccal administration, (36) 127
Buffer, (35) 165
Buffer effect, (37) 257
Buffer type and concentration, (37) 19
Bumadizone calcium, (34) 189
Buoyancy, (35) 157
Burette administration set, (31) 65; (36) 199
Butaperazine, (31) 69

Cab-O-Sil, (38) 255
Calcium gluceptate, (32) 213
Capacity factor, (36) 7
Capillary rheometry, (35) 235
Capping, (31) 201; (31) 271
Capsule, (34) 75; (34) 125
Carbopol, (40) 111
6-Carboxyfluorescein, (31) 231
6-Carboxylfluorescein, (31) 239
Carboxymethylcellulose (Blanose 7 MD), (39) 47
Carmofur, (38) 191
Carrier, (36) 157
Carrier-bound drug, (40) 215
Casein, (37) 103
Cefazolin, (40) 175
Cefmetazole, (33) 89
Cefotaxime, (34) 1
Cefotiam, (38) 179
Cefoxitin, (32) 151; (33) 99
Ceftazidime, (36) 55
Cell immobilization, (32) 61
Cellular interaction, (37) 135
Cellulose acetate filter, (34) 137
Cellulose derivative, (31) 175; (34) 93
Cellulose hydrogen phthalate, (33) 71
Cellulose propionate, (34) 137
Centperazine, (31) 169
Centrifuge method, (35) 111
Cephalexin, (32) 99
Cephalosporin, (32) 151; (34) 1; (34) 241
Cephalothin, (32) 151
Cerebrovascular endothelium, (32) 79
Cetostearyl alcohol, (31) 281
Cetrimide, (31) 281
Charge distribution, (36) 243
Charge transfer complex, (35) 129
Chemical denaturation, (39) 129
Chemical hydrolysis kinetics, (33) 15

Chemical stability, (31) 75; (32) 123; (38) 191
Chloramphenicol, (32) 91; (37) 11
Chlorhexidine, (34) 51; (36) 191
Chloride effect, (37) 257
Chloroquine, (31) 107; (34) 137
Chloroquine extraction from biological samples, (35) 173
Chloroxylenol, (32) 55
Chloroxylonol, (32) 91
Choline derivative, (39) 263
Chondroitin sulfate microsphere, (36) 253
Chylomicron, (33) 155; (34) 175
Ciliotoxicity, (31) 193; (31) 275
Cimetidine, (31) 33; (31) 119; (35) 181
Clonidine, (35) 21
Cloud point, (39) 263
Coarse-fine mixture, (36) 157
Coating, (37) 203
Cobalt, (40) 43
Colistin, (36) 55
Colloidal solution, (39) 121
Colonic absorption, (37) 49
Colonic motility, (31) 151
Colorectal absorption, (34) 111
Column dissolution, (36) 17
Combinative effect, (31) 239
Compactibility, (31) 201; (35) 29; (39) 207
Compaction, (36) 99; (40) 267
Compaction of binary mixture, (38) 109
Compaction performance parameter, (31) 201
Compaction pressure, (37) 119
Compactrol, (38) 255
Comparative evaluation of hypoglycemics, (38) 123
Comparison of HAPA-Gentamicin B with inactivation of other aminoglycosides, (37) 113
Compartment model, (31) 119
Compensation, (40) 1
Complement, (32) 165
Complement activation, (32) 165
Complexation, (35) 73
Complex coacervation, (32) 207
Complex formation, (37) 167
Composition of binder solution, (37) 155
Compressed tablet formulation, (40) 129
Compressibility, (31) 201
Compression, (37) 203
Compressional behaviour, (34) 169
Compression speed, (40) 15
Computer simulation, (34) 179; (36) 157
Concomitant administration, (38) 139
Conjunctival drug delivery, (38) 9
Consolidation, (35) 29; (36) 99
Contact angle, (38) 1
Content uniformity, (31) 145
Continuous matrix, (34) 169
Controlled drug release, (32) 143; (40) 33
Controlled release, (31) 15; (32) 99; (33) 65; (33) 243; (34) 57; (34) 169; (38) 65; (38) 109
Controlled-release formulation, (32) 85; (36) 73
Controlled-release pellet, (35) 253
Conversion of crystalline to amorphous forms by grinding, (32) 213
Convolution integral, (34) 57
Coprecipitates - PVP membrane distribution, (38) 99
Corneal hydrolysis, (37) 27
Corneal ocular absorption, (38) 9
Corneal permeability, (37) 27; (39) 229
Correlation in vitro–in vivo, (39) 235
Correlation of π values, (36) 7
Creatinine level, (34) 231
Creep, (36) 99
Creep analysis, (40) 267
Critical volume fraction, (34) 263
Crospovidone, (33) 115
Cross-linking, (31) 91
Crushing strength, (38) 255
Cryoprotectant, (33) 27
Cryoscopy, (34) 185
Crystal, (36) 17
Crystal forms of erythromycin, (38) 33
Crystallization, (34) 153
Crystal violet, (32) 91
Curcumin, (38) 247
Cutaneous delivery, (32) 199
Cyclodextrin, (31) 231; (33) 105
Cyclodextrin inclusion complex, (36) 223
Cystitis, (36) 233
Cytosine arabinoside (31) 185

Dapsone and derivatives, (32) 21
Daunorubicin, (31) 75; (34) 247
Daunorubicin and metabolites, (35) 219
DDT, (33) 155; (33) 165; (33) 173; (34) 175
Deceleration, (38) 265
Decomposition, (31) 25
Degradation, (31) 125; (34) 1
Degradation kinetics, (32) 111; (35) 61; (35) 165; (40) 157; (40) 193
Degradation kinetics in aqueous solution, (31) 75; (32) 123
Degradation mechanism, (32) 111; (38) 147; (40) 235
Degradation product of daunorubicin, (34) 247
Demethylation, (35) 259
Derivative UV spectroscopy, (35) 13; (40) 85
Dermal delivery, (35) 243
N-Desmethylflunitrazepam, (36) 113
Determination, (34) 29; (34) 183
Dexamethasone, (39) 229
cis-Diamminedichloroplatinum(II), (40) 51
Diazepam, (33) 37; (39) 213; (40) 223
Dibromopropamidine, (36) 191
Dibutyl phthalate, (33) 71
Dicumarol, (37) 103
Dielectric constant, (35) 91
Dielectrics, (38) 1
Diethyl ethoxymethylenemalonate, (33) 89
Diethyl maleate, (33) 89
Differential pulse polarographic analysis, (33) 105

Differential scanning calorimetry, (40) 129
Diffusion, (32) 71; (32) 79
Diffusional model, (32) 71
Diffusion cell, (35) 243; (36) 211; (37) 75
Diffusion coefficients (water), (31) 247
Diffusion from matrix, (37) 119
Diffusion mechanism, (39) 59
9-[(1,3-Dihydroxy-2-propoxy)-methyl]guanine, (35) 73
Dioctyl sodium sulfosuccinate, (37) 179
Di-*O*-methyl-*β*-cyclodextrin, (31) 25; (38) 265
Dioxane–water, (38) 71
Diphenhydramine, (35) 259; (36) 37
Diproprionate ester, (35) 73
DIP value – in vitro/in vivo correlation, (31) 15
Direct compression, (32) 93; (39) 93
Discontinuous absorption, (31) 119
Disinfectant, (34) 115
Disintegrant, (39) 201
Disintegrant compactibility, (32) 93
Disintegration, (37) 179; (39) 201
Disintegration mechanism, (32) 93
Disintegration time, (38) 109; (38) 255
Disodium cromoglycate, (35) 139; (37) 239; (39) 101; (39) 107
Dispersed matrix, (37) 41
Dispersion systems, (32) 13
Disposition, (31) 179
Disruption index, (39) 243
Dissolution, (31) 25; (31) 91; (31) 157; (32) 243; (32) 265; (33) 219; (34) 29; (35) 1; (35) 7; (37) 103; (37) 179; (38) 257; (39) 201; (40) 187
Dissolution in vivo, (40) 165
Dissolution of transdermal patches, (32) 243
Dissolution rate, (32) 171; (36) 17; (37) 119; (38) 191
Dissolution study, (33) 125; (36) 73
Dissolution testing, (37) 195
Distribution, (31) 209
Divalent cation, (31) 231
Dosage form strategy, (33) 173
Dose effect, (32) 133
Double labeling, (36) 17
Doxorubicin, (32) 123; (38) 257
Drug, (32) 71; (35) 129
Drug absorption, (33) 253; (34) 131; (38) 221; (39) 255
Drug absorption (gastrointestinal), (40) 165
Drug absorption interactions, (31) 107
Drug absorption models, (31) 107
Drug carrier, (36) 121
Drug delivery, (38) 91
Drug delivery system, (32) 21; (32) 71; (39) 173
Drug–excipient interaction, (37) 167; (40) 129
Drug formulation, (32) 187; (38) 247
Drug interaction, (36) 233
Drug lipophilicity, (32) 223
Drug loading in polymeric carrier, (33) 115
Drug metabolism, (33) 55; (37) 163
Drug migration, (34) 125
Drug–plastic interaction, (36) 199
Drug–polymer matrix, (38) 231
Drug release, (37) 41; (40) 111
Drug release from nanoparticle, (35) 121
Drug solubility, (32) 187
Drug sorption, (34) 137; (36) 199
Dry emulsion, (36) 81
Dry-powder inhalation, (35) 139
Dry powder inhaler, (39) 101
Dynamically modified silica, (32) 7
Dynamic dialysis, (36) 73

E. coli mutant, (36) 191
EDTA, (33) 89; (35) 227
[$Asu^{1,7}$]-Eel calcitonin, (33) 89
Effect of drug and vehicle on skin, (35) 243
Effect of fasting, (33) 155
Effect of food on absorption, (38) 221
Effect of mixing time on tablet properties, (36) 51
Effect of mobile phase composition, (36) 7
Effect of pH on drug release, (32) 143
Effect of receptor phase pH, (35) 103
Effect of vehicle on skin, (36) 211
Elasticity, (36) 99
Elastic recovery, (31) 99
Electrical interactive force, (39) 51
Electric charge, (37) 135; (37) 145
Electrochemical detection, (32) 7; (35) 219
Electrolyte, (38) 79
Electronic indicator, (36) 37
Electrophoretically controlled dermal drug application, (36) 37
Electrostatic adhesion, (36) 243
Electrostatic charge decay, (39) 51
Electrostatic charge measurement, (36) 243
Emulsion, (31) 281; (33) 99; (33) 235; (36) 131; (38) 79
Emulsion flocculation, (39) 33
Enalapril maleate, (40) 129
Enamine, (34) 157
Encapsulated volume, (35) 263
Endogenous creatinine clearance, (34) 231
Endotoxin, (40) 173
Enema spreading, (31) 151
Enema volume, (31) 151
Enhanced absorption, (37) 127
Enteric coated tablet, (32) 251; (37) 245
Enthalpy, (39) 243; (40) 1
Entropy, (39) 243; (40) 1
Entropy–enthalpy compensation, (38) 47
Enzymatic hydrolysis, (35) 73; (37) 87; (39) 75
Enzyme catalysis, (40) 249
Erbium-171, (32) 251
Erythromycin anhydrate, (38) 33
Erythromycin dihydrate, (38) 33
Escherichia coli, (35) 227
Ester prodrug, (39) 75
Estradiol, (35) 47
Estrogen, (35) 47
Ether–water, (36) 61; (36) 67
Ethoxylated amines, (32) 257
Ethyl acetoacetate, (33) 235; (40) 257

Ethyl cellulose, (31) 55; (34) 93
Ethylvinyl acetate, (34) 137
Eudragit, (38) 91
Eudragit compound, (32) 143
Eudragit E 30 D, (31) 43; (37) 211
Everted intestine, (40) 257
Everted sac, (38) 211
Everted sac, Doluisio method, (37) 75
Excess entropy, (39) 243
Excretion, (31) 83
Exogenous creatinine clearance, (34) 231
Explotab, (32) 269
Exsorption of griseofulvin, (40) 257
Extension device, (39) 107
External imaging, (32) 251
External scintigraphy, (35) 187
Extrarenal clearance, (34) 231
Extrusion, (35) 235

Facilitated transport, (32) 257
Factor X-fractionated heparin, (37) 65
Faraday cage, (36) 243
Fast dissolving dosage form, (40) 119
Fat droplet size determination, (34) 173
Fatigue testing, (39) 93
Fatty acid, (33) 99; (33) 225; (37) 127
Fenbufen, (40) 187
Film coat, (34) 67
Film coating, (31) 43; (37) 211
Film coating – polymer film, (39) 1
Film permeation, (33) 71
Filtration cell, (36) 223
First-pass metabolism, (31) 165; (36) 127; (38) 199
Fixed combination, (31) 179
Flow injection analysis, (33) 125
Flow-through dissolution method, (37) 195
Flucloxacillin, (32) 151
Flunitrazepam, (36) 113
Fluocinolone acetonide, (40) 105
Fluorescence detection, (32) 7
Fluorescence polarization, (33) 253
Fluorescent probe, (33) 253; (40) 93
5-Fluorocytosine, (35) 243
5-Fluorouracil, (32) 31; (36) 41; (36) 147
5-Fluorouracil and derivatives, (38) 239
Fluphenazine, (36) 187
Food, effects on gastrointestinal transit of controlled-release pellet, (35) 253
Force–displacement, (36) 99
Formaldehyde, (31) 91
Formulation, (31) 99; (36) 91; (36) 233; (38) 39; (39) 1
Formulation effects, (31) 271
Formulation influence on bioavailability, (37) 277
Fourier descriptor, (35) 81
Fracture energy, (36) 205
Fragmental values, (31) 209
Fragmentation propensity, (37) 155
Free energy, (39) 243; (40) 1
Free solute mechanism, (34) 179
Freeze-fracture electron microscopy, (35) 263
Freezing rate, time and temperature, (33) 27
Frusemide, (31) 65
Fusarium oxysporum, (32) 61
Fusion, (39) 243

Gamma scintigraphy, (32) 85; (37) 245; (39) 189
Gamma-spectroscopy, (32) 251
Gas adsorption, (39) 207
Gas chromatography, (32) 61
Gastric emptying, (34) 213; (35) 187; (39) 163
Gastric emptying time, (33) 235
Gastric retention, (35) 157
Gastrointestinal absorption, (33) 235
Gastrointestinal pH, (37) 245
Gastrointestinal tract, (39) 255
Gastrointestinal transit, (32) 85; (35) 253
Gastro-oesophageal reflux, (39) 163
Gelatin, (31) 91; (34) 125; (35) 177
Gelation, (34) 263
Gelucire, (38) 91
General shape, (37) 41
Gentamicin, (31) 193; (35) 121
Germination, (34) 51
Glibenclamide, (38) 123
Glucose, (36) 61
Glucose level, (34) 157
Glyceride, (33) 181; (37) 127
Glycerol, (33) 71; (34) 125; (36) 61
Glyceryl trinitrate, (39) 183
Glycolic acid derivative, (39) 75
Glyoxylic acid, (37) 185
Granulation, (33) 81; (37) 155; (40) 73
Granulation end-point, (31) 277; (32) 177
Granulation monitoring, (31) 277; (32) 177
Granulation of a model system, (33) 81
Granule, (31) 131
Granule property, (33) 81
Griseofulvin, (33) 235; (40) 257
Ground mixture, (31) 25
Group additivity parameter, (38) 251

Hairless mouse skin, (36) 211
Hairless rat, (32) 31
Haloperidol, (34) 23
HAPA-Gentamicin B, (37) 113
pH-dependent polymer, (33) 71
Healthy human, (34) 157
Heat denaturation, (39) 129
Heat of solution, (40) 1
pH effect, (37) 257
Heparin, (37) 65
Hexachlorobenzene, (34) 175
Hexobarbital, (34) 9
Hexyl nicotinate, (36) 91
HI-6, (40) 193
High-affinity (HA-FX) fraction, (37) 65

High-performance liquid chromatography, (31) 75; (32) 111; (32) 123; (33) 55
High-pressure liquid chromatographic analysis, (32) 133; (35) 219
Higuchi model, (37) 41
Histology, (40) 187
Homogeneity, (31) 145
Homologous series, (36) 7
Honeybee venom, (37) 163
HPLC, (31) 125
HPLC of the opiates, (32) 7
HPMC and Na CMC, (39) 39
pH–rate profile, (35) 165
Human, (33) 181; (40) 125
Human growth hormone, (34) 35
Human interferons α and β, (34) 111
Human natural interferon β (INFβ)), (32) 103
Human recombinant interferon α_2 (IFNα_2), (32) 103
Human serum albumin, (36) 113
Human skin (in vivo), (40) 105
Humidity, (33) 257
Hyamine method, (34) 29
Hydration, (31) 247; (34) 153
Hydrocolloid, (35) 157
Hydrocortisone, (36) 67
Hydrodynamically balanced system, (35) 157
Hydrolysis, (31) 125; (37) 185
Hydrolysis kinetics, (37) 257
Hydrolysis rate, (35) 193; (40) 235
Hydrophilic matrix tablet, (31) 169
Hydrophilic plasticizer, (33) 71
Hydrophilic polymer, (38) 65
Hydrophilic polymer matrix, (35) 201
Hydrophobic effect, (32) 237
Hydrophobicity, (34) 131
Hydrophobic plasticizer, (33) 71
Hydrophobic polymer, (32) 71
Hydrotrope, stability, (34) 17
N-Hydroxyalkylation, (37) 185
Hydroxybenzoate, (33) 105; (38) 257
p-Hydroxy benzoate esters, (32) 223
1(2-Hydroxyiminomethyl-pyridinium)-2-(4-carboxyamido-pyridinium)dimethylether dichloride, (40) 193
4-Hydroxyisophthalic acid, (40) 85
α-Hydroxy-*N*-benzoylglycine derivative, (37) 185
Hydroxypropyl cellulose, (34) 67
Hydroxypropyl methylcellulose, (31) 55; (34) 67; (38) 65; (40) 223
Hygroscopic material, (34) 153
Hyoscine, (32) 159

Ibuprofen, (32) 229; (37) 175
Immunomodulating compound, (37) 33
Immunomodulator, (39) 255
Immunonanosphere, (39) 173
Improved bioavailability, (31) 165
Improved dissolution system, (33) 115
Improved drug delivery, (31) 165
Impurity distribution, (36) 17
Inactivation of HAPA-gentamicin B by penicillins, (37) 113
Inclusion complex, (31) 25; (33) 105
Inclusion complexation, (35) 193; (38) 191; (38) 265
Indentation hardness, (31) 201
Indomethacin, (31) 157; (32) 207; (33) 195; (33) 219; (39) 235; (40) 223
Inert matrix, (35) 21
Inhalation behaviour, (35) 139
Inhibition, (35) 73
Inhibition effect for stress ulcer, (35) 181
Injector, (36) 141
Insoluble additives, (31) 43
Insoluble excipient, (37) 211
Insulin, (36) 199; (38) 83
Insulin suppository, (34) 157
Interaction, (34) 189; (34) 207; (38) 99
Interaction phenomena, (39) 1
Interaction terms, (31) 209
Interactive mixture, (35) 111; (36) 243
Interactive system, (39) 51
Interferons, enteric absorption, (34) 111
Intestinal absorption, (31) 231; (31) 239; (34) 35; (36) 121
Intestinal transport and degradation, (37) 33
Intestine, (33) 155
Intralipid, (39) 33
Intramesenteric venous injection, (36) 131
Intramolecular bonding, (34) 23
Intramuscular formulation, (40) 193
Intramuscular injection, (36) 147; (37) 145; (38) 39; (38) 133
Intranasal, (34) 131
Intranasal drug absorption, (31) 193
Intraocular pressure, (32) 47; (39) 229
Intravenous fluid, (33) 261
Intravenous injection, (37) 145
Intrinsic dissolution rate, (38) 109
Inulin, (38) 9
Inulin clearance, (34) 231
In vitro degradation, (33) 1
In vitro diffusion, (35) 91; (35) 103; (38) 99; (40) 93
In vitro dissolution, (32) 21
In vitro drug release, (32) 223; (32) 229
In vitro model, (34) 179
In vitro release, (39) 129
In vitro skin model, (39) 149
In vitro skin models, (32) 257
In vitro skin penetration, (40) 101
In vitro transport, (37) 103
In vivo decomposition, (33) 1
In vivo kinetics, (40) 201
In vivo performance, (31) 15
In vivo release characteristics, (33) 195
Iodine antiseptic, (34) 45
Iodine, molecular interaction, (35) 129
Ion exchange resin, (40) 119
Ionizing radiation, (37) 1; (40) 173
Ion pair, (39) 59
IRI level, (34) 157

γ-Irradiation sterilization, (32) 151
Irritable bowel, (40) 151
Isokinetic relationship, (38) 47
Isonicotinic acid, (34) 81
Isopropyl myristate, (39) 149
Isosorbide dinitrate, (39) 183
Isotope, (32) 251
Isotropic system, (31) 271; (34) 169

Kaolin–pectin mixture, (36) 187
Kaopectate, (34) 207
Ketoprofen, (34) 189
Killing of *Leishmania donovani*, (40) 215
Kinetic release in vitro, (39) 235
Kinetics, (31) 125; (38) 147; (38) 161
Kinetics of hydrolysis, (35) 39
Kinetics of release, (37) 119
Kupffer cell, (36) 253

β-Lactam antibiotics, (32) 151
Lactose, (35) 29; (39) 207; (40) 15
Lactose BP, (36) 29
Lag time, (34) 179
Lamination, (31) 271
Laser velocimetry, (36) 91
Latex, (37) 203
Lattice disruption, (40) 1
Lecithin, (33) 181; (38) 83
Leishmaniasis, (40) 215
Levamisole, (39) 255
Lipid digestion, (34) 175
Lipophilicity, (32) 79; (36) 41
Lipophilic prodrug, (36) 147
Lipopolysaccharide (LPS) mutant, (35) 227
Liposomal entrapment, (37) 75; (40) 143
Liposome, (33) 27; (34) 163; (34) 179; (36) 147; (36) 165; (37) 233; (39) 213; (40) 51; (40) 81
Liposome characterization, (35) 263; (37) 171
Liposome disposition in vivo, (37) 233
Liquid chromatography, (34) 1
"Liquid Gaviscon", (34) 105
Liquid membrane phenomenon, (32) 39; (38) 239
Liquid paraffin, (34) 185
Liver endothelial cell, (36) 253
Log P, (38) 47
Long action, (35) 187
Lorazepam, (40) 119
Low-affinity (LA-FX) fraction, (37) 65
Lower urinary tract infection, (36) 233
LPS mutant, (34) 115
Lubrication, (31) 131; (40) 15
Lymphatic absorption, (40) 257
Lymphatic delivery, (34) 175; (36) 147
Lymphatic targeting, (31) 185
Lymphatic transport, (33) 155; (33) 165; (33) 173
Lyophilisation, (34) 17

Macromolecular prodrug, (35) 39
Macromolecules, (32) 171
Macrophages, (32) 165
Magnesium stearate, (31) 131; (36) 51
Magnesium trisilicate, (34) 207; (36) 187
Magnetic drug targeting, (40) 201; (40) 207
Magnetic microparticle, (40) 201; (40) 207
N-Mannich base, (35) 243
Material behavior, (36) 205
Mathematical modeling, (38) 23
Mathematical model of drug carrier capture, (40) 201
Mathematic model of drug kinetics, (40) 207
Matrix formation, (34) 169
Matrix tablet, (40) 223
Measurement of adhesion, (35) 111
Mechanical activation, (32) 93
Mechanical property, (39) 1
Mechanical strength of tablet, (37) 155
Mechanism, (38) 161
Mechanism of action, (35) 129
Mechanism of ciliotoxicity, (31) 275
Mechanism of dissolution, (34) 197
Mechanism of drug delivery, (34) 57
Mechanism of release, (37) 211
Medium-chain glyceride, (36) 131
Megaloporous system, (31) 15; (34) 57
Melphalan, (37) 257
Membrane permeability modification, (37) 49
Menadione, (39) 137
Menadione sodium bisulfite, (39) 137
6-Mercaptopurine, (35) 165; (36) 211
Mesenchymal cell, (40) 23
Metabolism, (39) 23
Metered dose aerosol, (39) 107
Methacrylate butadiene styrene, (34) 137
Methadone, (33) 249
Methodology, (33) 155
Methotrexate-α,γ-dialkyl ester, (36) 7
Methylated β-cyclodextrin, (38) 191
Methylated cyclodextrin, (35) 193
Methyl caproate, (33) 235; (40) 257
2-Methyl-1,4-naphthalene diol, (39) 137
Methyl propionate, (33) 235; (40) 257
Methyl salicylate, (35) 91
Methylxanthine, (33) 55
Metoclopramide, (31) 33
Metoprolol, (34) 131; (37) 251
Metoprolol tartrate, (39) 39
Metronidazole, (31) 99; (38) 65
Metronidazole monosuccinate dextran ester conjugate, (35) 39
Micellar solubilization, (37) 49
Michaelis-Menten metabolism, (34) 9
Microanalysis, (31) 131
Microcalorimetry, (38) 251
Microcapsule, (32) 207; (33) 243; (40) 165
Microcrystalline cellulose, (31) 137; (34) 217; (38) 227; (40) 129; (40) 267
Microdispersed enteric coating, (34) 259
Microelectrophoresis, (32) 207

Microencapsulation, (31) 91; (33) 243; (35) 145
Micro-enema, (33) 249
Microfilaricidal agent, (31) 169
Micronization, (35) 81; (35) 139
Microparticulate ophthalmic delivery system, (40) 81
Microsphere, (32) 165; (34) 225; (35) 177; (39) 189
Midazolam maleate, (33) 37
Miglyol 812, (33) 99
Mild condition micronization , (32) 265
Milk, (33) 125; (36) 73; (36) 187
Mineral oil, (34) 35
Miosis, (39) 113
Mitomycin C, (32) 111; (32) 133
Mitomycin C–dextran conjugate, (37) 135; (37) 145
Mixed micelle, (31) 231; (39) 263
Mixed solvents, (32) 187
Mixer torque rheometer, (38) 227
Modelling, (38) 79; (39) 141
Modelling of process, (36) 81; (40) 33
Modified drug release, (39) 267
Modified release, (32) 1; (37) 211
Moisture, (33) 257
Molecular dispersion, (31) 25
Molecular weight, (37) 135; (37) 145
Molecular weight determination, (34) 185
Monoclonal antibody, (39) 173
Morphology, (40) 23
Mouse, (36) 1
Mouse tail-flick method, (38) 171
Mucosal barrier, (38) 211
Mucus glycoprotein, (35) 211
Mucus layer, (38) 211
Multilamellar vesicle, (35) 263; (37) 171
Multiparticulate system, (34) 213
Multiple emulsion, (38) 133
Multiple regression analysis, (38) 23
Multivesicular vesicle, (37) 171
Multivitaminic preparation, (40) 43
Murine plasma fibronectin, (37) 233
Myotic response, (33) 187

Nadolol, (37) 127
Nafarelin, (31) 125
Nafcillin, (32) 151
Nalbuphine, (38) 199
Nalidixic acid, (38) 71
Naloxone, (33) 225; (36) 127
Naltrexone, (36) 127; (38) 171
Nanocapsule, (36) 121
Nanoparticle, (33) 45; (34) 145; (35) 121; (40) 23; (40) 81
Naphthalene solubilities, (31) 225
Naphthyl ester hydrolysis, (35) 61
Naproxen, (32) 85; (37) 245; (38) 117
Narcotic antagonist, (38) 171
Nasal absorption, (39) 87
Nasal delivery, (39) 189
Nebulisation, (36) 55
Negatively charged liposomes, (32) 237
Neoplastic tissue, (35) 219
Neutral liposomes, (32) 237
Neutron activation, (32) 251
Nifedipine, (31) 179
Nipagin A, (39) 47
Nipasol M, (39) 47
Nitrofurantoin, (33) 125; (34) 29; (35) 145; (37) 103
Nitrofurantoin, macrocrystalline, (36) 105
Nitroglycerin patches, (32) 243
Nitroprusside, (33) 1
^{31}P-NMR, (35) 263
Non-aqueous media, (39) 59
Non-compartmental analysis, (38) 139
Non-corneal absorption, (34) 163
Non-corneal ocular absorption, (38) 9
Non-disintegrating matrix, (38) 231
Non-isothermal kinetics, (34) 1
Non-linear least-squares analysis, (31) 33; (34) 9
Noxythiolin, (38) 59
NSC-267213, (38) 147; (38) 161
Numerical deconvolution, (40) 165
Nutritive mixture, (38) 79

n-Octanol, (36) 165
Octanol/DMF–Water partition coefficient, (36) 7
Ocular, (34) 163
Ocular bioavailability, (37) 19; (39) 113
Ocular hydrolysis, (33) 15
Oesophageal mucosa, (34) 75
Oestradiol, (32) 159
Off-line sampler, (36) 175
Oil, (33) 99
Oleic acid, (31) 239; (34) 175
Oleic acid: Shape factor, (36) 17
Ophthalmic gels, (32) 47
Ophthalmic preparation, (37) 11
Ophthalmic solution, (37) 19
Ophthalmic vehicles, (31) 261
Opioid, (38) 199
Opioid antagonist, (36) 127
Opsonin, (32) 165
Optimization techniques, (38) 23
Oral absorption, (36) 41
Oral and rectal bioavailability, (38) 191
Oral bioavailability, (38) 179
Oral contraceptive, (33) 55
Oral drug delivery, (37) 75; (40) 143
Oral floating dosage form, (35) 157
Oral form, (40) 33
Ordered mixing, (31) 145; (36) 51
Ordered mixture, (36) 157
Organic hydrogels, (31) 261
Organic solvent, (35) 173
Osteogenic sarcoma, (40) 23
Outer membrane, (32) 55
Outgrowth, (34) 51
Overcoat, (37) 211
Overlapping pK_a-values, (31) 69

Oxazepam, (40) 119
Oxprenolol, (37) 251
Oxyphenbutazone, (32) 171

Packaging, (33) 257
Paraben, (35) 227
Paracetamol, (36) 29; (40) 15
Parameters of drug loading, (40) 63
Parenchymal cell, (36) 253
Parenteral, (31) 9; (36) 141
Parenteral fat emulsion, (34) 173
Parenteral infusion fluids, (31) 1
Parenteral nutrition, (38) 79
Parenteral solution, (40) 175
Partial and total cohesion parameters, (34) 217
Partial solubility parameter, (34) 217
Particle adhesion, (35) 111; (39) 51
Particle deposition, (37) 239; (39) 101; (39) 107
Particle detachment, (35) 111
Particle interaction, (34) 263; (36) 243
Particle–particle interaction, (37) 167
Particle size, (35) 29; (35) 81; (36) 205; (40) 111
Particle size determination, (34) 173
Particle size of carrier, (36) 51
Particle texture, (39) 207
Partition coefficient, (32) 79; (33) 15; (34) 125; (34) 241; (38) 47
Partitioning, (36) 61; (36) 67
Paste formation, (40) 73
Peanut oil, (34) 175
Pectin, (31) 91
Pellet, (37) 203
Penetration enhancer, (32) 31; (32) 257; (33) 225
Pentobarbitone, (38) 261
Peppermint oil, (40) 151
Peptide, (31) 125
Percolation theory, (38) 109
Percolation threshold, (38) 109
Percutaneous absorption, (32) 31; (32) 257; (33) 225; (34) 179; (39) 149; (40) 101; (40) 105; (40) 111
Permeability, (32) 55; (36) 61; (36) 67
Permeation, (39) 59
Perphenazine, (36) 187
Pharmaceutical, (36) 141
Pharmaceutical formulation, (40) 85
Pharmaceutical processing, (40) 1
Pharmaceutical salts, (33) 201
Pharmaceutics, (40) 129
Pharmacodynamics, (38) 123
Pharmacokinetic behaviour, (37) 145
Pharmacokinetics, (31) 179; (32) 133; (33) 55; (36) 41; (36) 105; (36) 127; (37) 97; (37) 219; (38) 117; (38) 123; (38) 261; (39) 141; (40) 151
Pharmacokinetics of intradermal interferon, (32) 103
Phase transitions of crystalline hydrate and crystalline anhydrate, (32) 213
Phenacetin, (32) 269
Phenobarbitone, (31) 107
Phenolic, (35) 227
Phenol red, (36) 131; (39) 87
Phenothiazine, (36) 187
L-Phenylalanine mustard, (37) 257
Phenylephrine, (32) 47
Phenylpropanolamine, (39) 141
Phenytoin, (32) 171; (34) 29; (35) 7
Phillips MK II, (36) 141
Phonophoresis, (40) 105
Phosphoramide mustard, (37) 257
Phosphorylated mitosene degradation products, (32) 111
Photoaffinity label, (36) 113
Photoallergy, UV light, (35) 259
Photobinding, (36) 113
Photochemical stabilizer, (38) 247
Photodecomposition, (35) 259
Photodegradation, (31) 1; (31) 65
Photolysis, (38) 265
Photosensitivity, (38) 265
Physical characterization of drug–polymer system, (40) 63
Physical property, (35) 139
Physiological model, (37) 219
Pig cornea, (37) 27; (39) 229
Pigskin, (35) 91; (35) 103
Pilocarpine, (31) 261; (33) 45; (33) 187; (37) 19
Pilocarpine hydrochloride, (39) 229
Pilocarpine prodrug, (39) 113
Plasma concentrations, (33) 181
Plasma esterase, (40) 249
Plasma glucose, (38) 83
Plastic, (39) 183
Plastic compression, (31) 99
Plasticity, (36) 99
Plasticizer, (37) 203
Plasticizing efficiency, (31) 55
Plasvita TSM, (38) 255
Pluronic, (40) 93
Pluronic F68, (33) 65
Pluronic F-127, (39) 121
Pluronic F-127 gels, (32) 223
Point of zero charge and pH relationship, (34) 263
Poloxamer 338, (34) 145; (40) 93
Poloxamer hydrogel, (33) 65
Poloxamine 908, (34) 145
Poly(acrylamide), (31) 261
Polyacrylamide microparticles, (32) 165
Poly(acrylic acid), (31) 261; (38) 65
Polyacryl starch microparticle, (40) 215
Polyacrylstarch microparticles, (32) 165
Polyalkylcyanoacrylate, (36) 121; (40) 23
Polyalkylcyanoacrylate nanoparticle, (39) 213
Poly(butyl 2-cyanoacrylate), (34) 145
Poly(butylcyanoacrylate) nanoparticle, (33) 45
Polybutylcyanoacrylate nanoparticles, (33) 187
Poly(ϵ-caprolactone), (35) 145
Polyethylene, (36) 99
Polyethylene glycol, (31) 55;(31) 157; (31) 175; (33) 219; (40) 111

Polyethylene glycol 6000 blend, (34) 93
Poly(hexylcyanoacrylate) nanoparticle, (33) 45
Poly(hydroxybutyrate), (37) 41
Poly(hydroxyvalerate), (37) 41
Polymer compression, (34) 169
Polymeric gel, (40) 93
Polymeric matrix, (35) 21; (37) 119
Polymer interaction, (34) 93
Polymer matrix, (32) 143; (35) 145; (40) 33
Polymer membrane, (39) 59
Polymethacrylic nanoparticle, (39) 173
Polymethylmethacrylate, (35) 177
Poly(methylmethacrylate) nanoparticle, (33) 45
Polymorph, (31) 157; (35) 181
Polymorphism, (34) 23; (40) 1
Poly(oxyethylene) glycol, (34) 67
Polypeptide drug, (34) 35
Polyplasdone XL, (38) 255
Polystyrene, (34) 137
Polystyrene beads, (40) 63
Polyvinyl alcohol, (33) 219
Polyvinylchloride, (34) 137; (39) 183
Polyvinylpyrrolidone, (31) 157; (32) 13; (32) 229; (33) 219; (37) 175; (38) 39; (38) 99
Polyvinylpyrrolidone interaction, (37) 167
Polyvinylpyrrolidone molecular weight, (34) 45
Porosigen, (38) 231
Porous polymers, (32) 71
Positively charged liposomes, (32) 237
Possible antithyroid effect, (35) 129
Potassium chloride, (35) 201
Potassium citrate, (36) 233
ζ-Potential, (39) 33
Povidone–iodine, (34) 45
Powder, (38) 1
Powder mixing, (31) 145
Powder segregation, (31) 145
Powder storage, (39) 51
Powder with very high surface area, (32) 265
Pralidoxime chloride, (40) 157
Prediction, (37) 15
Prediction of solubilities in binary solvents, (31) 225
Prediction-titration, (37) 19
Prednisolone, (35) 1; (39) 129
Preservative, (39) 47; (39) 229
Pressor activity, (38) 99
Presystemic metabolism, (31) 165
Primaquine–microparticle complex, (40) 215
Primojel, (38) 255
Prodrug, (31) 165; (32) 199; (33) 15; (35) 243; (36) 41; (37) 87; (37) 185; (38) 179; (38) 199
Prodrug activation, (36) 233
Prolongation of release, (37) 119
Promethazine hydrochloride, (40) 223
Promotion of intestinal absorption, (36) 131
Promotive absorption, (31) 239
Propantheline bromide, (33) 125
Propranolol, (31) 275; (33) 243; (37) 251
Propranolol hydrochloride, (39) 39; (40) 223
Propranolol isomers, (31) 275
Propylene glycol, (31) 9
Propylene glycol–water, (38) 71
Propyphenazone, (37) 179
Prostacyclin, (35) 193
Prostaglandin-E_2, (33) 65
Prostaglandin $F_{2\alpha}$, (37) 27
Prostaglandin $F_{2\alpha}$ ester, (37) 27
Protriptyline, (38) 265
Proxyphylline, (38) 139
Pseudomonas aeruginosa, (32) 55
Psoriasis treatment, (35) 61
Pupil diameter viscosity of ophthalmic gels, (32) 47
PVP retarding effect, (34) 197
Pyridylalkanamide, (38) 47

QSAR study, (38) 251
Qualitative histology, (40) 181
Quantification, (32) 1
Quantitative structure/activity relationship, (34) 241
Quaternary ammonium compound, (36) 191
Quinidine, (34) 207

Rabbit, (39) 87
Rabbit duodenal epithelium, (37) 33
Rabbit eye, (32) 47
Radiolabeled tablet, (35) 187
Radiolabelled magnetic drug carrier, (40) 201
Radiotracer method, (33) 257
Raft-forming antacid, (34) 105; (39) 163
Rat, (36) 1; (37) 219; (38) 261; (40) 181; (40) 187
Rat colonic absorption, (33) 89
Rate constants (water), (31) 247
Rate-controlled release, (35) 21
Rate diffusion, (33) 71
Rat small intestinal epithelial cell, (33) 253
Reaction kinetics, (31) 1
Rearrangement, (35) 259
Rectal absorption, (31) 185; (33) 249; (36) 41
Rectal administration, (33) 195; (38) 117
Relative spreading, (38) 103
Release kinetics, (36) 175
Release mechanism of theophylline, (40) 63
Release mechanisms, (33) 137
Release of adriamycin, (33) 147
Release rate, (37) 135
Release rate from suppository, (38) 191
Remoxipride, (40) 165
Respiratory tract, (37) 239; (39) 101; (39) 107
Response–surface modeling, (38) 23
Reticuloendothelial system, (37) 233
Reversed-phase HPLC, (35) 13
Reversed phase liquid chromatography, (36) 7
RH-composition phase diagram, (32) 213
Rheological synergism, (39) 39
Rheology, (38) 227
Riboflavin, (35) 157

Rifamycin, (38) 39
Rotating diffusion cell, (32) 257; (39) 149
Routine analysis, (39) 137
RU 41740, (37) 33

Salicylamide, (31) 165; (33) 125
Salicylate, (34) 157; (40) 111
Salicylic acid, (35) 103; (37) 195; (38) 71; (39) 255
Salicylic acid plasma concentration, (34) 259
Salmonella typhimurium, (34) 115
Salt, (35) 165
Salt form selection, (33) 201
Sample size relationship, (36) 157
Scanning electron microscopy, (40) 129
γ-Scintigraphy, (34) 145; (38) 221; (40) 81; (40) 119
Scleral drug delivery, (38) 9
Second derivative spectroscopy, (34) 29
Semi-synthetic penicillins, (32) 151
Sensitivity and resistance, (36) 191
Sequential release of metronidazole, (35) 39
Serum, (39) 141
Shape feature, (35) 81
Sheep, (38) 39
Shelf life, (40) 175
Silica, (36) 81
Silicone rubber, (35) 21
Simeco tablet, (34) 207
Site of administration, (33) 173
Size, (36) 157
Size distribution, (35) 263; (36) 157
Skin, (36) 61; (36) 67; (39) 23
Skin enzyme, (39) 23
Skin penetration cell, (40) 101
Skin transport, (32) 31
Small angle X-ray scattering, (35) 263
Sodium benzoate, (39) 47
Sodium caprylate, (33) 253
Sodium carboxymethylcellulose, (34) 183
Sodium cefazolin, (31) 231
Sodium chloride, (36) 29; (36) 99; (40) 15
Sodium cholate, (31) 157; (37) 127
Sodium cromoglycate, (39) 189
Sodium diclofenac, (33) 181; (40) 125
Sodium salicylate, (32) 143; (33) 89; (33) 253; (34) 17; (34) 35; (36) 81; (38) 83; (38) 91; (40) 33
Solid dispersion, (34) 197; (37) 175; (38) 83
Solid dispersion system, (31) 157; (33) 219; (34) 29; (35) 1; (35) 7
Solid drug dispersions, (32) 229
Solid matrix, (37) 119
Solid solution, (36) 17; (39) 243
Solid-state chemistry, (40) 129
Solid-state interaction, (37) 167
Solubility, (31) 69; (32) 171; (35) 91; (35) 103; (36) 41; (40) 1
Solubility in binary solvent, (38) 71
Solubility parameter, (31) 175; (36) 211; (38) 71
Solubility study, (36) 223
Soluble complex, (34) 197
Sorption, (39) 183
Specific gravity, (35) 187
Spectrophotometry, (34) 81; (39) 137; (40) 43
Spherical form, (36) 81
Spherical oral dosage device, (38) 91
Spheric bead, (40) 33
Spheronisation, (35) 235
Spray-dried lactose, (39) 201
Spray drying, (35) 29; (35) 139; (37) 239
Stability, (31) 9; (31) 125; (31) 281; (33) 27; (37) 87; (37) 257; (38) 59; (38) 79; (38) 147; (38) 161; (40) 175; (40) 235
Stability and antitumor activity in vitro, (40) 51
Stability constant, (35) 193; (38) 191
Stabilization, (35) 73; (35) 193
Stabilization temperature, (33) 147
Stagnant diffusion layer, (37) 49
Standard deviation, (36) 157
Starch microsphere, (36) 253
Steady-state assumption, (34) 179
Sterilization, (37) 1; (40) 173
Steroids, (32) 61
Steroid transformation, (32) 61
Stratum corneum, (31) 247
Stressing study, (38) 23
Stress relaxation, (36) 99
Structural modification, (38) 161
Structure–activity relationship, (39) 149
Structure/response correlation, (39) 113
Substrate-labeled fluorescent immunoassay (SLFIA), (36) 1
Sulfamethizole, (37) 103
Sulfanilamide, (39) 255
Sulfonamide, (37) 87
Sulfoxide, (33) 225
Sulphamethizole, (37) 41
Sulphanilamide, (40) 73
Sulpiride, (37) 277
Sulpiride–food interaction, (37) 277
Sulpiride–propantheline interaction, (37) 277
Supercritical gases, (32) 265
Supersaturation phenomena, (34) 197
Suppository, (33) 195; (33) 249; (38) 83; (39) 235; (40) 181; (40) 187
Suppository, γ-Scintigraphy, (38) 103
Surface-active agents, (31) 193
Surface acylation, (32) 21
Surface adsorption interactions, (31) 137
Surface contact, (40) 129
Surface reaction of particles, (32) 21
Surfactant, (31) 193; (33) 225; (37) 179; (39) 87; (40) 73
Surfactant effects on absorption, (37) 49
Sustained release, (31) 43; (32) 21; (33) 173; (33) 243; (34) 259; (35) 201; (36) 81; (38) 133; (38) 171; (40) 93; (40) 125; (40) 223
Sustained release dosage form, (37) 97
Sustained release effect, (33) 187
Sustained release formulation, (35) 157
Sustained release preparation, (35) 21; (40) 151
Sustained release suppositories, (33) 181

Sustained release tablet, (31) 169
Swellable matrix tablet, (39) 39
Swelling, (32) 93; (38) 65
Synthetic gastric liquid, (32) 143
Synthetic membrane, (35) 91; (35) 103
Syringeability, (36) 141
Syringe pump, (39) 183

Tablet, (34) 75; (34) 153; (36) 205; (39) 201; (40) 125
Tablet binding agents, (32) 269
Tablet compression, (36) 29
Tablet disintegrating agents, (32) 269
Tablet formulation, (38) 23
Tablet friability, (32) 269
Tablet hardness, (32) 269
Tableting, (31) 99
Tableting property, (35) 29
Tablet strength, (39) 207
Tablet testing, (39) 93
Tablet weight, (40) 15
Technetium-99m labelling, (37) 239; (39) 101; (39) 107
Technetium-99m–dextran, (34) 145
Temazepam, (31) 9; (34) 17
Temperature, (40) 175
Temperature effect, (35) 165
Tenoxicam, (37) 219
Tensile strength, (31) 201; (36) 99
Testing methods – viscometry and solubility, (39) 1
Testosterone, (33) 65
Tetracycline, (38) 211
Tetracycline binding, (35) 211
Tetracycline hydrochloride, (40) 223
1,2,3,4-Tetrahydronaphtaline derivative, (38) 99
Theolin retard, (31) 15
Theophylline, (31) 15; (33) 55; (34) 57; (34) 153; (35) 243; (36) 73; (37) 97; (38) 139; (40) 63; (40) 223
Theoretical partition coefficient, (36) 211
Thermal analysis, (36) 223; (40) 129
Thermal analysis – NMR, X-ray, IR, (39) 1
Thermal gelation, (39) 121
Thermodynamic activation parameter, (35) 193
Thermodynamics, (38) 47; (39) 243
Thermodynamics of partitioning, (36) 165
Thermogravimetric analysis, (40) 129
Thiamphenicol glycinate, (40) 85
Thioridazine, (36) 187
Thiourea, (36) 61
Three-compartment open model, (38) 139
Through-flow cell, (39) 235
Tiaprofenic acid, (35) 253
Ticarcillin, (32) 151
Timolol, (32) 159; (33) 15; (38) 9
Timolol ester, (33) 15
Tissue concentration, (37) 219
Tissue distribution, (39) 213
Tissue interaction, (39) 213
Tobacco smoking, (33) 55
α-Tocopherol, (32) 39
Topical drug, (39) 23
Topical effect, (36) 91
Topical ophthalmic drugs, (31) 261
Topical selective drug delivery, (34) 163
Torsional braid pendulum, (31) 55
Total parenteral nutrition, (39) 33
Toxicity, (32) 251; (40) 23
Transdermal application, (36) 37
Transdermal delivery, (33) 37
Transdermal drug delivery, (32) 159
Transdermal opioid, (33) 225
Transdermal therapy, (39) 23
Transfer of cationic drugs across lipoidal membrane, (37) 251
Transformation, (34) 153
Transient diffusion, (36) 81
Transmission electron microscope, (34) 173
Triboelectrification, (36) 243
Trifluoperazine, (33) 89; (36) 187
Trifluperidol, (34) 23
Two-compartment model, (31) 33
Two-compartment open model, (38) 139

Ufasome, (31) 239
Ulceration, (32) 13
Ultrafiltration, (32) 171
Ultrasound, (40) 105
Ultraviolet absorbance detection, (32) 7
UNIQUAC, (31) 209; (32) 187
Unit dose, (33) 257
Urea, (36) 61; (36) 67
Urethane, (38) 261
Urinary excretion, (36) 105; (40) 125
Urine, (39) 141
Urine acidification, (36) 233
Urine alkalinisation, (36) 233
Urine excretion, (33) 181
USP paddle dissolution method, (37) 195
UV diode array detection, (35) 13
UV fluorescence microscopy, (31) 145
UV radiation, (31) 1
UV/visible spectroscopy, (35) 129

Variability, (34) 183
Vasodilator, (36) 91
Vehicle, (35) 243
Vehicle effects, (33) 165
Vehicle volume, (33) 165
Vibration analysis, (31) 277; (32) 177
Viscometry and solubility, (39) 1
Viscosity, (32) 13; (35) 91; (36) 141; (39) 47; (40) 93
Vitamin A, (31) 1
Vitamin C, (31) 83
Vitamin E, (32) 39
Vitamin E deficiency, (32) 39

Water vapor transmission rate (WVTR), (33) 257
Water vapour, (31) 247
Wavelength dependence, (31) 1

Wet powder, (35) 235
Wettability, (38) 1
Wetting, (38) 1
Wicking, (32) 93
Work of failure, (39) 93

X-ray, thermal analyses, apparent water solubilities, (32) 213
Xylan, (38) 255

Young's modulus of elasticity, Pharmaceutical material, (37) 15

Zeparox, (36) 29
Zero-order release, (34) 57; (35) 21; (35) 201; (39) 39
Zeta potential, (39) 47

MANUSCRIPTS should be submitted **in quadruplicate** in English and be accompanied by a list of **6–8 key words**. All data that would help referees to evaluate the paper should also be supplied.

Full length papers
should be typewritten with double spacing on one side of the sheet only, should be divided into **Summary** (including **key words**), Introduction, Materials and Methods, Results and Discussions,
should be accompanied by a separate sheet bearing Title, Author's names and their affiliations.
should not **normally** exceed 10 printed pages (18 typescript pages) in length.

Short communications should not be divided into sections i.e. Introduction etc. They preferably should have a 20–50 word Summary and a full reference list should be provided.

Descriptions/reviews of computer programs should include in the manuscript information on hardware compatibility and software availability (including costs, ordering address, etc.). All manuscripts must be accompanied by a manual describing software validation; operating instructions (in greater detail than in the manuscript) and illustrations of input and output data sets. In order that reviewers can appropriately evaluate the package, three copies of the manual and software (diskettes, tapes, etc.) should accompany submission. Software and manuals will be returned only upon request by the authors.

Tables should be compiled on separate sheets with a short descriptive title, a legend and/or footnotes identified by a, b, c, etc.

Figures
Line drawings (including graphs) should be drawn in black ink on white paper. Lettering should be in proportion to the figure to allow for reduction to page format.
Half-tone figures should be sharp, high-contrast original prints on glossy paper.
The magnification of micrographs should be indicated by **a scale bar in the figure**.
If figures are not to be reduced their format should not exceed 16 × 20 cm. All legends should be typed double spaced on separate sheets.

References

Should be assembled alphabetically on a separate sheet. In the text they should be referred to by name and year (Harvard System). More than one paper from the same author in the same year must be identified by the letters a, b, c, etc. placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be given followed by et al. Literature references must consist of names and initials of all authors, title of paper referred to, abbreviated title of periodicals and the volume, year and first **and last** page numbers of the paper. Periodicals, books and multi-author books should accord with the following examples:

Kaplan, S.A., Weinfeld, R.E. and Lee, T.L., Semiautomated spectrophotofluorometric determination of trimethoprim in biological fluids. J. Pharm. Sci., 62 (1973) 1865–1870.
D'Arcy, P.F. and Griffin, J.P., Latrogenic Diseases, Oxford University Press, London, 1972, p. 11.
Johnson, C.A., International problems in the control of medicines. In Deasy, P.B. and Timoney, R.F. (Eds.), The Quality Control of Medicines, Elsevier, Amsterdam, 1976, pp. 83–95.

Abbreviations of journal titles should follow the system used by the ISDS List of Serial Title Word Abbreviations, 1985, but beginning each word with a capital

Proofreading will be undertaken by the Publisher. *Correspondence and queries relating to proofs* should be directed to the publishers: IJP, Elsevier Science Publishers B.V., P.O. Box 1527, 1014 AG Amsterdam, The Netherlands. Telephone: (20) 5803465. Proofs will not be sent out unless specifically requested by the author(s) when the paper is submitted and so indicated on the title page. No alteration of substance to the text, tables or legends will be accepted.

Page Charge There will be no page charge.

Reprints Fifty reprints of each paper will be provided free of charge. Additional copies may be ordered at prices shown on the reprint order form which will be sent to the author.

Subscriptions
1988: Volumes 41–47 (7 volumes in 21 issues).
Dfl. 1834.00 (US$ 991.25) + Dfl. 182.00 (US$ 98.50) postage, packaging and handling.
Total Price Dfl. 2016.00 (US$ 1089.75). The Dutch guilder price is definitive. The US $ price is subject to exchange rate fluctuations and is therefore only given as a guide.

Journals are sent by surface delivery to all countries, except the following countries where SAL air delivery (Surface Airlifted Mail) is ensured: U.S.A., Canada, Japan, Australia, New Zealand, P.R. China, India, Israel, South Africa, Malaysia, Singapore, South Korea, Taiwan, Pakistan, Hong Kong, Brazil, Argentina, Mexico and Thailand. Airmail rates for other countries are available on request.

Subscription orders can be entered only by calendar year (January–December) and should be sent to: **Elsevier Science Publishers B.V., Journals Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, Telex 18582 ESPA NL**, or to your usual subscription agent. Claims for missing issues should be made within three months of publication, otherwise they cannot be honored free of charge. The Publisher reserves the right to issue additional volumes during the course of the year. Such volumes will be invoiced before publication and delivered receipt of payment.

In the U.S.A. and Canada: All questions arising **after acceptance** of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publishers, **Elsevier Science Publishers B.V. (Biomedical Division) P.O. Box 1527, 1000 BM Amsterdam, The Netherlands**. For further information and personal subscriptions, contact: **Elsevier Science Publishers, Journal Information Center, 52 Vanderbilt Avenue, New York, NY 10017. Tel.: (212) 370-5520**.

Advertising. Apply to W.J. van Cattenburch (Advertising Manager), P.O. Box 211, 1000 AE Amsterdam, The Netherlands. (Tel. (20) 5803714.)

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CONTENTS

Author Index 1
Subject Index 17

© 1988 Elsevier Science Publishers B.V. (Biomedical Division). All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Cited in: Current Contents (Life Sciences; Clinical Practice); International Pharmaceutical Abstracts; Biological Abstracts; Chemical Abstracts; Excerpta Medica EMBASE; Index Medicus

Printed in The Netherlands